

Index to Volume 12

The index to Volume 12 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in

Clinical Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages	Issue	Pages
January	1-84	July	469-548
February	85-164	August	549-628
March	165-244	September	629-708
April	245-324	October	709-788
May	325-388	November	789-868
June	389-468	December	869-948

Subject Index

A

Acaceainide; blood levels; fluorescence polarization methods, 49
N-Acetyl-l-tyrosine; excretion; excretion, infants, parenteral nutrition, 606
N-Acetylprocainamide, see Acaceainide
Acquired immunodeficiency syndrome atovaquone; pneumonia therapy, FDA approvals, 175 didanosine, comparison, zalcitabine; therapy, efficacy, NIAID clinical studies, 391 stavudine; therapy, parallel track policy, FDA approvals, 7 unapproved drugs; imports, AIDS buyers' clubs, FDA regulations, 632 zalcitabine, comparison, didanosine; therapy, efficacy, NIAID clinical studies, 391
Acyclovir; chickenpox; rational therapy, AAP recommendations, 175
Addicts; opiates; levomethadyl maintenance, narcotic treatment programs, 797
Administration hospital pharmacy; NSAIDs, DUE criteria, 780 Food and Drug Administration; accelerated drug approvals, final regulations, 253
Adrenergic agents, see **Sympathomimetic agents**
Adverse reactions, see **Drugs, adverse reactions**
Advertising; industry, pharmaceutical; accelerated drug approvals, FDA regulations, 253
Advertising Index, 84, 164, 244, 324, 388, 468, 548, 628, 708, 788, 868, 935
AIDS, see **Acquired immunodeficiency syndrome**
Age patients; effects, mexiletine pharmacokinetics, 768 pediatrics; N-acetyl-l-tyrosine, excretion, infants, nutrition, 606
Agency for Health Care Policy and Research; grants; pharmacists' role, health care, 474
Agranulocytosis; sargramostim; therapy, sulfasalazine toxicity, 179
Albumin human; effects; serum protein levels, parenteral nutrition, 377
Albumins; replacement solutions; selection, clinical studies, review, 335
Aldesleukin; use; evaluation, criteria, 853
Allergies drugs; photosensitivity, review, 580 temafloxacin hydrochloride; hemolytic anemia, 380
Alprazolam; premenstrual syndrome; therapy, psychological symptoms, 181
Alzheimer's disease; tacrine hydrochloride; therapy, FDA approvals, 873
American Academy of Pediatrics acyclovir; chickenpox therapy, AAP recommendations, 175 chloral hydrate; pediatric use, recommendations, 876

American Journal of Hospital Pharmacy; journals; merging, *Clinical Pharmacy*, 526, 923
American Society of Hospital Pharmacists journals; AJHP, *Clinical Pharmacy*, merging, 526, 923 protocols; antimicrobial prophylaxis, colorectal surgery, 399
Amino acids; dietary supplements; athletes, ergogenic effects, 900
Aminoglycosides gentamicin; pharmacokinetics, prediction, vancomycin pharmacokinetics, 909 gentamicin sulfate; body distribution, septic shock, 131; pharmacokinetics, term newborn twins, 615 tobramycin; pharmacokinetics, prediction, vancomycin pharmacokinetics, 909 tobramycin sulfate; body distribution, septic shock, 131
Amiodarone photosensitivity; toxicity, review, 580 toxicity; thyroid dysfunction, therapy, 774
Amlodipine besylate; marketing; FDA approvals, 93
Amoxicillin; bismuth and metronidazole; peptic ulcer therapy, *H. pylori*, review, 34
Analgesics and antipyretics fentanyl; transdermal pain therapy, 718 meperidine hydrochloride; patient-controlled analgesia, DUE criteria, 150 morphine; fentanyl replacement pain therapy, 718 morphine sulfate; patient-controlled analgesia, DUE criteria, 150 premenstrual syndrome; therapy, headache, 181
Anaphylaxis; replacement solutions; review, 335
Anemia epoetin alfa; therapy, DUE criteria, 925 temafloxacin hydrochloride; hemolytic, adverse reactions, 380
Anesthetics midazolam hydrochloride; follicular fluid levels, in vitro fertilization, 770 propofol; toxicity, aggressive sex behavior, 449
Anesthetics, local; benzocaine; allergies, photosensitivity, review, 580
Angina pectoris; amlodipine besylate; therapy, FDA approvals, 93
Angiotensin-converting-enzyme inhibitors hypertension; systolic, therapy, geriatrics, review, 347 proteinuria; therapy, nephrotic syndrome, review, 429
Antacids; labeling; nonprescription drugs, FDA regulations, 800
Anthraclyclines; toxicity; extravasation, dimethyl sulfoxide therapy, 560
Antiarrhythmic drugs, see **Cardiac drugs**
Antidiarrheal agents; labeling; nonprescription drugs, FDA regulations, 800
Antiemetics; labeling; nonprescription drugs, FDA regulations, 800
Antianemia drugs; epoetin alfa; DUE criteria, 925
Antibiotics aztreonam and clindamycin; or metronidazole, colorectal surgery, prophylaxis, 399 clindamycin and aztreonam; colorectal surgery, prophylaxis, 399 cystic fibrosis; therapy, review, 657 septic; septic, therapy, review, 829 vancomycin; pharmacokinetics, geriatrics, 481; pharmacokinetics, prediction, 909 vancomycin hydrochloride; dosage, calculations, computers, 126; pharmacokinetics, dosage, hematologic malignancy, 515
Antibodies; monoclonal; graft vs. host disease, prophylaxis, transplantation, 736; septic shock therapy, review, 829
Anticoagulants enoxaparin; FDA approvals, 471 glomerulonephritis; membranoproliferative, therapy, review, 429 heparin; dosage estimation, pharmacokinetic models, 599; low molecular weight, cerebrovascular disorders therapy, review, 359; myocardial infarction therapy, 197 heparins; low-molecular-weight vs. unfractionated, thrombophlebitis, 892 ticlopidine hydrochloride; toxicity, cholestasis, 398 warfarin; atrial fibrillation, atrial flutter therapy, 721; myocardial infarction therapy, 197
Anticonvulsants diazepam; seizures, therapy, ondansetron adverse reactions, 613 felbamate; marketing, FDA approvals, 713 phenytoin; unbound, blood levels prediction, equations, 913 valproic acid; toxicity, pancreatitis, review, 440
Antidepressants premenstrual syndrome; therapy, psychological symptoms, 181 sertraline hydrochloride; interactions, tranylcypromine, serotonergic syndrome, 222 tranylcypromine sulfate; interactions, sertraline, serotonergic syndrome, 222
Antiemetics; ondansetron hydrochloride; adverse reactions, seizures, 613
Antifungals; itraconazole; FDA approvals, 6
Antihistamines; loratadine; FDA approvals, 474
Anti-infective agents atovaquone; pneumonia therapy, FDA approvals, 175 metronidazole; and aztreonam, colorectal surgery, prophylaxis, 399; peptic ulcers, *H. pylori*, combined therapy, review, 34; diarrhea, therapy, cefixime toxicity, 881 pentamidine; toxicity, pancreatitis, review, 440 peritonitis; therapy, effects, α_1 -acid glycoprotein concentrations, 602
Anti-inflammatory agents methotrexate; asthma therapy, overview, 762 nonsteroidal; DUE criteria, 780; polymyalgia rheu-

matica therapy; review, 571; proteinuria therapy, nephrotic syndrome, review, 429
sunlinda; toxicity, pancreatitis, review, 440

Antilipemic agents; nephrotic syndrome; complications, therapy, review, 429

Antimanic agents; lithium; DUE criteria, 617

Antineoplastic agents
 adesleukin; DUE criteria, 853
 asparaginase; toxicity, pancreatitis, review, 440
 cladribine; FDA approvals, 391; leukemia therapy, review, 805
 finasteride; prostatic hypertrophy therapy, review, 15
 leucovorin calcium, comparison, levoeucovorin calcium; equivalency, i.v. vs. oral, availability, 293
 levoeucovorin calcium, comparison, leucovorin calcium; equivalency, i.v. vs. oral, availability, 293
 mercaptopurine; toxicity, pancreatitis, review, 440
 nephrotic syndrome; therapy, review, 429
 paclitaxel; refractory ovarian neoplasms therapy, review, 401
 teniposide; FDA approvals, 6
 toxicity; anemia, epoetin alfa therapy, DUE criteria, 925

Antithymocyte globulin; graft vs. host disease; prophylaxis, bone marrow transplantation, 736

Antithyroid drugs
 hyperthyroidism; therapy, 774
 propylthiouracil; hyperthyroidism therapy, 774

Antituberculars; resistance; *M. tuberculosis*, health professions, surveillance programs, 167

Antivirals
 acyclovir; chickenpox therapy, AAP recommendations, 175
 didanosine; toxicity, pancreatitis, review, 440
 didanosine, comparison, zalcitabine; AIDS therapy, efficacy, NIAID clinical studies, 391
 ribavirin; bronchiolitis therapy, pediatrics, review, 95
 stavudine; AIDS therapy, parallel track policy, FDA approvals, 7
 zalcitabine, comparison, didanosine; AIDS therapy, efficacy, NIAID clinical studies, 391

Anxiolytics, sedatives and hypnotics
 chloral hydrate; pediatric use, AAP recommendations, 876
 labeling; nonprescription drugs, FDA regulations, 800
 zolpidem tartrate; insomnia therapy, review, 814

Arrhythmia; sotalol hydrochloride; therapy, review, 883; ventricular, therapy, FDA approvals, 176

Arteritis; relationship; giant cell, polymyalgia rheumatica therapy, 571

Arthritis; anti-inflammatory agents; nonsteroidal, therapy, DUE criteria, 780

Asparaginase; toxicity, pancreatitis, review, 440

Aspergillosis; prednisone; allergic bronchopulmonary, therapy, review, 24

Asthma; methotrexate; therapy, overview, 762

Athletes; dietary supplements; ergogenic effects, 900

Alovaquone
 marketing; FDA approvals, 175
 pneumonia; *P. carinii*, therapy, review, 563

Atrial fibrillation; therapy, review, 721

Atrial flutter; therapy, review, 721

Availability, drugs, see Drugs, availability

Azathioprine; toxicity, pancreatitis, review, 440

Aztreonam; and clindamycin or metronidazole; colorectal surgery, prophylaxis, ASHP protocols, 399

B

Bacterial infections; anti-infective agents; colorectal surgery, prophylaxis, ASHP protocols, 399

BCG vaccines; immunization; tuberculosis, health professions, surveillance programs, 167

Benzocaine; photosensitivity; adverse reactions, review, 580

Benzodiazepine antagonists; flumazenil; DUE criteria, 536; overdose, therapy, review, 641; rational therapy, overdose, overview, 691; respiratory depression therapy, benzodiazepine toxicity, 483

Benzodiazepines
 overdose; toxicity, flumazenil therapy, DUE criteria, 536
 toxicity; overdose, flumazenil therapy, overview, 691; overdose, flumazenil therapy, review, 641; respiratory depression, flumazenil therapy, 483

Bezoars; nifedipine; toxicity, sustained-action tablets, 849

Binding
 phenytoin; proteins, unbound levels prediction, 913
 quinidine; plasma, effects, ultrafiltration, 917

Bioavailability, see Drugs, availability

Biotechnology; shock; septic, therapy, review, 829

Bipolar disorder; lithium; therapy, DUE criteria, 617

Bismuth ulcers; peptic, combined therapy, *H. pylori*, review, 34

Blastomycosis; itraconazole; therapy, FDA approvals, 6

Blood levels
 acecainide; fluorescence polarization methods, 49
 N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606
 α -acid glycoproteins; and dialysate, effects, peritonitis, 602
 clonidine hydrochloride; infant, maternal consumption, lactation, 178
 gentamicin; pharmacokinetics, term newborn twins, 615
 lidocaine hydrochloride; monitoring, pharmacists' role, 527
 N-5-methyltetrahydrofolate; leucovorin-levoleucovorin generic equivalency, 293
 midazolam hydrochloride; follicular fluid, in vitro fertilization, 700
 phenytoin; prediction, equations, unbound concentration, 913
 procainamide; fluorescence polarization methods, 49
 reserpine; binding, effects, ultrafiltration, 917; fluorescence polarization vs. EMIT, 49

tetrahydrofolic acid; leucovorin-levoleucovorin generic equivalency, 293

vancomycin; dosage calculations, computers, 126; pharmacokinetics, geriatrics, 481

Blood; resuscitation; clinical studies, review, 335

Bone neoplasms; strontium chloride Sr 89; pain therapy, FDA approvals, 632

Book Reviews, 76, 240, 323, 387, 467, 627, 704, 787, 864, 933

Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Third Edition, 323

Cancer: Principles and Practice of Oncology, 4th Edition, 864

The Chemotherapy Source Book, 240

Clinical Epidemiology: A Basic Science for Clinical Medicine, Second Edition, 866

Clinical Pharmacokinetics Pocket Reference, 933

Clinical Pharmacology: Basic Principles in Therapeutics, Third Edition, 76

Clinical Pharmacy and Therapeutics, Fifth Edition, 704

Drugs in Anesthetic Practice, Seventh Edition, 241

Drug Susceptibility in the Chemotherapy of Mycobacterial Infections, 82

Essentials of Basic Science: Pharmacology, 704

Geriatric Nutrition: The Health Professional's Handbook, 933

Handbook of Cancer Chemotherapy, Third Edition, 241

Handbook of Clinical Drug Data, Seventh Edition, 706

Handbook of Medical Toxicology, 627

Handbook of Psychotropic Drugs, 242

Management of HIV Infection in Infants and Children, 787

Martindale: The Extra Pharmacopoeia, 30th Edition, 934

Patient Recruitment in Clinical Trials, 387

Progress in Basic and Clinical Pharmacology, Vol. 9: Effects of Drugs on Human Functioning, 867

Tardive Dyskinesia, 467

Textbook of Clinical Neuropharmacology and Therapeutics, Second Edition, 707

Books Received, 84, 164, 324, 388, 468, 548, 627, 707, 787, 867, 935

Boots Pharmaceuticals; flosequinan; product withdrawal, toxicity, 713

Bromocriptine; premenstrual syndrome; therapy, mastodynia, 181

Bronchiolitis; therapy; pediatrics, review, 95

C

Calcium antagonists
 atrial fibrillation; therapy, and atrial flutter, 721
 felodipine; hypertension therapy, review, 261
 hypertension; systolic, therapy, geriatrics, review, 347
 isradipine; hypertension therapy, review, 261

Calcium regulators
 gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117
 pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117

Calculations
 aminoglycosides; pharmacokinetics, prediction, 909
 creatinine; clearance, estimation, gynecologic neoplasms, 685
 phenytoin; dosage, unbound, blood levels prediction, 913
 vancomycin; dosage, computer programs, 126

Cancer, see Antineoplastic agents

Cancer drugs, see Antineoplastic agents

Carbohydrates; nutrition; support, respiratory tract diseases, 276

Carcinogenicity; chloral hydrate; toxicity, lack, 876

Cardiac drugs
 amiodarone; photosensitivity, toxicity, review, 580;
 toxicity, thyroid dysfunction, therapy, 774

amlodipine besylate; FDA approvals, 93

antiarrhythmic agents; atrial fibrillation, atrial flutter therapy, 721

digoxin; atrial fibrillation, atrial flutter therapy, 721

flosequinan; high dose, toxicity, clinical studies, 474; product withdrawal, toxicity, 713

isosorbide dinitrate; systolic hypertension therapy, geriatrics, review, 347

lidocaine hydrochloride; pharmacokinetics monitoring, pharmacists' role, 527

magnesium; myocardial infarction therapy, mechanism of action, review, 588

metixinide; pharmacokinetics, middle-aged and elderly patients, 768

nifedipine; toxicity, bezoars, sustained-action tablets, 849

procainamide; blood levels, fluorescence polarization methods, 49

procainamide hydrochloride; side effects, lack, pregnancy, 58

quinidine; binding, blood levels, effects, ultrafiltration, temperature, 917; blood levels, fluorescence polarization vs. EMIT, 49

sotalol hydrochloride; arrhythmia therapy, review, 883; FDA approvals, 176

Carnitine; dietary supplements; athletes, ergogenic effects, 900

Cathartics and laxatives
 glycerin; enemas vs. suppositories, neonates, 846
 labeling; nonprescription drugs, FDA regulations, 800

Catheters; intravenous; pressure, extravasation prediction, infants, 216

Cefepime; pharmacokinetics; cholecystectomy, acute cholecystitis, 134

Cefixime; toxicity; diarrhea, metronidazole therapy, 881

Centocor; product withdrawal; nebacumab, 254

Central nervous system stimulants; tacrine hydrochloride; marketing, FDA approvals, 873

Cephalosporins
 cefepime; pharmacokinetics, cholecystectomy, acute cholecystitis, 134
 cefixime; toxicity, diarrhea, metronidazole therapy, 881

Cerebrovascular disorders
 therapy, review, 359

ticlopidine; therapy, DUE criteria, 64

Certifications; specialties; pharmacists, pharmaceutical care, ASHP, 923

Chickenpox; acyclovir; rational therapy, AAP recommendations, 175

Chloral hydrate; pediatrics; AAP recommendations, 876

Cholecystitis; cefepime; pharmacokinetics, cholecystectomy, 134

Cholestasis; ticlopidine hydrochloride; toxicity, 398

Ciprofloxacin; use; evaluation, criteria, 226

Cisapride; marketing; FDA approvals, 876

Cladribine
 leukemia; therapy, review, 805
 marketing; FDA approvals, 391

Clearance, see Extrcretion

Clindamycin; and aztreonam; colorectal surgery, prophylaxis, ASHP protocols, 399

Clinical Pharmacy
 acknowledgment to reviewers—October 1, 1992, to September 30, 1993, 923
 journals; merging AJHP, 526, 923
 instructions for submitting computer disks with revised manuscripts, 63, 535
 procedure for submission of manuscripts to journals published by the American Society of Hospital Pharmacists, 61, 533

Clinical studies
 nebacumab; marketing, withdrawal, toxicity, 254
 didanosine, comparison, zalcitabine; AIDS therapy, efficacy, 391
 drugs; alerts, NIH guidelines, news media, 637
 flosequinan; high dose, toxicity, mortality, 474
 replacement solutions; resuscitation, review, 415; resuscitation, selection, review, 335
 women; gender-related differences, FDA regulations, 395; new drugs, FDA regulations, 712

zalcitabine, comparison, didanosine; AIDS therapy, efficacy, 391

Clomipramine; premenstrual syndrome; therapy, psychological symptoms, 181

Clonazepam; concomitant therapy, 222

Clonidine hydrochloride; lactation; maternal consumption

tion, infant blood levels, 178
Cobamamide; dietary supplements; athletes, ergogenic effects, 900
Cognition
 enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; toxicity, hypertension therapy, 300
 hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; toxicity, hypertension therapy, 300
 propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; toxicity, hypertension therapy, 300
Colitis
 cefixime; toxicity, metronidazole therapy, 881
 mesalamine; ulcerative, therapy, FDA approvals, 555
Colloids; replacement solutions; clinical studies, review, 415; selection, clinical studies, review, 335
Combined therapy
 cyclosporine and methotrexate; graft vs. host disease, marrow transplantation, 736
 methotrexate and cyclosporine; graft vs. host disease, marrow transplantation, 736
 ulcers; peptic, *H. pylori*, review, 34
Commentaries, 53, 527
Communication; clinical studies; results, prepublication clinical alerts, NIH, 637
Compounding; quinacrine hydrochloride; pleurodesis solutions, tablets, 693
Computers; programs; calculations, vancomycin dosage, 126
Contraceptives, injectable; medroxyprogesterone acetate; marketing, FDA approvals, 92
Contraceptives, oral; premenstrual syndrome; therapy, 181
Contraindications; itraconazole, 6
Correction Notices, 14, 558, 803, 881
 Are antiarrhythmic drugs obsolete? (Aug 1992 Commentary), 14
 Cladrabine approved as first-line therapy for hairy cell leukemia (Jun 1993, News), 558
 Flumazenil: a benzodiazepine antagonist (Sep 1993, Drug Review), 803
 Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia (Nov 1993, Drug Reviews), 881
Costs
 anticoagulants; thrombophlebitis therapy, 892
 cladribine; leukemia therapy, review, 805
 new-drug applications; Prescription Drug User Fee Act of 1992, pharmaceutical industry, 3
 replacement solutions; resuscitation, review, 335
CP Continuing Education, 67, 154, 235, 314, 383, 460, 542, 622, 699, 783, 860, 929
Creatinine; clearance; estimation, gynecologic neoplasms, 685
Crystalloids; replacement solutions; clinical studies, review, 415; selection, clinical studies, review, 335
Current Literature, 74, 161, 238, 318, 385, 465, 544, 624, 702, 785, 863, 932
Cyclosporine
 alone and with methotrexate; graft vs. host disease, prophylaxis, marrow transplantation, 736
 nephrotic syndrome; therapy, review, 429
 use; evaluation, criteria, transplant recipients, 696
Cystic fibrosis
 quinacrine hydrochloride; pneumothorax therapy, pleurodesis solution, 693
 therapy; review, 657
Cytotoxic agents, see **Antineoplastic agents**

D

Dalteparin; thrombophlebitis; low molecular weight heparins vs. unfractionated, 892
Danazol; premenstrual syndrome; therapy, 181
Dependence; opiates; levomethadyl therapy, regulations, 797
Depression; lithium; therapy, DUE criteria, 617
Devices; medical; clinical studies, women, FDA regulations, 712; reports, MEDWatch, FDA programs, 529
Dextran; replacement solutions; selection, clinical studies, review, 335
Dialysis
 heparin; therapy, temafloxacin adverse reactions, 380
 peritoneal; peritonitis, effects, α_1 -acid glycoprotein concentrations, 602
Diarrhea; cefixime; toxicity, metronidazole therapy, 881
Diazepam; seizures; therapy, ondansetron adverse reactions, 613
Didanosine
 comparison, zalcitabine; AIDS therapy, efficacy, NIAID clinical studies, 391
 toxicity; pancreatitis, review, 440
Dietary supplements; athletes; ergogenic effects, 900
 Digoxin; atrial fibrillation; therapy, and atrial flutter, 721
Dimethyl sulfoxide; mechanism of action; anthracycline extravasation therapy, 560
Diphtheria and tetanus toxoids and pertussis vaccines; combination, *Haemophilus b* oligosaccharide conjugate vaccines; marketing, FDA approvals, 391
Diuretics
 furosemide; toxicity, pancreatitis, review, 440
 hypertension; therapy, protocols, 53
 nephrotic syndrome; complications, therapy, review, 429
 premenstrual syndrome; fluid retention therapy, 181
 thiazides; systolic hypertension therapy, geriatrics, review, 347
Documentation; drugs, adverse reactions; MEDWatch, FDA programs, 529
Dosage
 aldesleukin; DUE criteria, 853
 amiodipine besylate, 93
 anti-inflammatory agents; nonsteroidal, DUE criteria, 780
 atovaquone, 175; *P. carinii* pneumonia, therapy, review, 563
 ceferpine; pharmacokinetics, cholecystectomy, acute cholecystitis, 134
 ciprofloxacin; DUE criteria, 226
 cisapride, 876
 cladribine, 391; leukemia therapy, review, 805
 cyclosporine; DUE criteria, transplant recipients, 696
 diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, marketing, 391
 enoxaparin, 471
 epoetin alfa; DUE criteria, 925
 felbamate, 713
 felodipine; hypertension therapy, review, 261
 fentanyl; transdermal pain therapy, 718
 finasteride; prostatic hypertrophy therapy, review, 15
 flosequinan; high, toxicity, clinical studies, 474; high, toxicity, product withdrawal, 713
 flumazenil; 536
 gentamicin sulfate; term newborn twins, 615
 heparin; estimation, pharmacokinetic models, 597
 indometacin; injections, DUE criteria, neonates, 232
 isradipine; hypertension therapy, review, 261
 itraconazole, 6
 lidocaine hydrochloride; protocols, pharmacokinetics monitoring, pharmacists' role, 527
 lithium; DUE criteria, 617
 lomefloxacin; DUE criteria, 452
 loratadine, 474
 medroxyprogesterone acetate, 92
 meperidine hydrochloride; patient-controlled analgesia, DUE criteria, 150
 mesalamine, 555
 molgramostim; side effects, bone marrow transplantation, 520
 morphine sulfate; patient-controlled analgesia, DUE criteria, 150
 ofloxacin; DUE criteria, 452
 overdose; benzodiazepines, flumazenil therapy, review, 691; benzodiazepines, flumazenil therapy, review, 641; benzodiazepines, flumazenil-use criteria, 536
 paclitaxel; refractory ovarian neoplasms therapy, review, 401
 phenytoin; unbound, blood levels prediction, equations, 913
 sotalol hydrochloride, 176; arrhythmia therapy, review, 883
 strontium chloride Sr 89, 632
 tacrine hydrochloride, 873
 teniposide, 6
 ticlopidine; DUE criteria, 64
 vancomycin hydrochloride; calculations, computers, 126; pharmacokinetics, hematologic malignancy, 515
 warfarin; DUE criteria, 307
 zolpidem tartrate; insomnia therapy, review, 814
Dosage forms
 glycerin; enemas vs. suppositories, neonates, 846
 leucovorin calcium, comparison, levoeucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 levoeucovorin calcium, comparison, leucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 mesalamine; sustained-action, oral, FDA approvals, 555
Dosage schedules
 anti-inflammatory agents; nonsteroidal, long-term therapy, DUE criteria, 780
 gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117
 metoclopramide; lactation stimulation, therapy, 479
 pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117
 prednisone; allergic bronchopulmonary aspergillosis therapy, review, 24
Drug abuse; therapy; levomethadyl maintenance, narcotic treatment programs, 797
Drug administration routes
 leucovorin calcium, comparison, levoeucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 levoeucovorin calcium, comparison, leucovorin calcium; i.v. vs. oral, equivalency, availability, 293
 quinacrine hydrochloride; intrapleural, pleurodesis solution, pneumothorax therapy, 693
Drug administration sites; intravenous; pressure, catheter extravasation prediction, infants, 216
Drug administration; cladribine; leukemia therapy, review, 805
Drug information; new drugs; evaluative reviews, publications, need, 306
Drug interactions
 drugs; nonprescription; new labeling requirements, FDA, 800
 itraconazole, 6
 sertraline hydrochloride and tranylcypromine sulfate; serotoninergic syndrome, 222
 tranylcypromine sulfate and sertraline hydrochloride; serotoninergic syndrome, 222
Drug Reaction Alerts, 74, 161, 238, 318, 385, 465, 544, 624, 702, 785, 863, 932
Drugs
 new; marketing, FDA approval, 1992, 247; publications, evaluative reviews, need, 306
 unapproved; imports, AIDS buyers' clubs, FDA regulations, 632
Drugs, adverse reactions
 see also **Toxicity**
 ondansetron hydrochloride; seizures, nausea therapy, 613
 photosensitivity; allergies, review, 580
 replacement solutions; review, 335
 reports; MEDWatch, FDA programs, 529
 temafloxacin hydrochloride; hemolytic anemia, kidney failure, 380
Drugs, availability
 leucovorin calcium, comparison, levoeucovorin calcium; equivalency, oral vs. i.v., 293
 levoeucovorin calcium, comparison, leucovorin calcium; equivalency, oral vs. i.v., 293
Drugs, body distribution
 aminoglycosides; pharmacokinetics, septic shock, 131
 clonidine hydrochloride; lactation, infant, blood levels, 178
 gentamicin sulfate; term newborn twins, 615
 midazolam hydrochloride; follicular fluid levels, in vitro fertilization, 770
 vancomycin; pharmacokinetics, geriatrics, 481; prediction, pharmacokinetics, 909
 vancomycin hydrochloride; pharmacokinetics, hematologic malignancy, 515
Drugs, investigational
 investigational new drugs; stavudine, AIDS therapy, parallel track policy, 7
 new-drug applications; accelerated, FDA approvals, final regulations, 253; clinical studies, women, FDA regulations, 712; Prescription Drug User Fee Act of 1992, FDA approvals, 3
Drugs, nonprescription; labeling; FDA regulations, 800
Drug use; evaluation; aldesleukin, criteria, 853; ciprofloxacin, criteria, 226; cyclosporine, criteria, transplant recipients, 696; epoetin alfa, criteria, 925; flumazenil, criteria, 536; indometacin injections, criteria, neonates, 232; lithium, criteria, 617; lomefloxacin, ofloxacin, criteria, 452; NSAIDs criteria, 780; patient-controlled analgesia, criteria, 150; ticlopidine, criteria, 64; warfarin, criteria, 307
Ductus arteriosus; indomethacin; patent, therapy, DUE criteria, neonates, 232
DUE Criteria, 64, 150, 226, 307, 452, 536, 617, 696, 780, 853, 925
 aldesleukin, 853
 ciprofloxacin, 226
 cyclosporine, 696
 epoetin alfa, 925
 flumazenil, 536
 indomethacin, 232
 lithium, 617
 ofloxacin and lomefloxacin, 452
 nonsteroidal anti-inflammatory drugs (NSAIDs), 780
 patient-controlled analgesia, 150
 ticlopidine, 64
 warfarin, 307

E

Editorials, 306, 526, 691, 923
 Context of a transition, 923
 Judicious use of flumazenil, 691
 The new *AJHP*, 526
 Reviews of new drugs, 306
Education; pharmaceutical; residencies; pharmaceutical care, ASHP, 923
Enalapril maleate; comparison, hydrochlorothiazide, propranolol hydrochloride; effects, cognition, motor activity, quality of life, 300
Encephalopathy; muromonab-CD3; toxicity, graft resection, 610
Endotoxins; shock; septic, therapy, review, 829
Enemas; glycerin; vs. suppositories, neonates, 846
Enoxaparin
 marketing; FDA approvals, 471
 thrombophlebitis; low-molecular-weight heparins vs. unfractionated, 892
Enzymes; cystic fibrosis; digestive, therapy, 657
Epilepsy; felbamate; therapy, FDA approvals, 713
Epoetin alfa; use; evaluation, criteria, 925
Equations
 aminoglycosides; pharmacokinetics, prediction, 909
 creatinine; clearance, estimation, gynecologic neoplasms, 685
 heparin; dosage estimation, 597
 phenytoin; unbound, blood levels prediction, methodology, 913
Equivalency, generic
 leucovorin calcium, comparison, levoeucovorin calcium; i.v. vs. oral, availability, 293
 levoeucovorin calcium, comparison, leucovorin calcium; i.v. vs. oral, availability, 293
Equivalency, therapeutic
 fentanyl, comparison, morphine; dosage, pain, 718
 morphine, comparison, fentanyl; dosage, pain, 718
Estrogens
 estrogen; premenstrual syndrome therapy, 181
 toxicity; pancreatitis, review, 440
Excretion
 N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606
 cefepime; clearance, cholecystectomy, acute cholecystitis, 134
 creatinine; clearance, estimation, gynecologic neoplasms, 685
 gentamicin sulfate; term newborn twins, 615
 mexiletine; clearance, middle-aged and elderly patients, 768
 vancomycin; clearance, prediction, 909; models, clearance, dosage calculations, 126
 vancomycin hydrochloride; clearance, hematologic malignancy, 515
Extravasation
 anthracyclines; toxicity, dimethyl sulfoxide therapy, 560
 injections; i.v. pressure, prediction, infants, 216

F

Fat emulsions; intravenous; respiratory tract diseases, review, 276
FDA Medical Products Reporting Form and Instructions, 71, 531
Felbamate; marketing; FDA approvals, 713
Felodipine; hypertension; therapy, review, 261
Fentanyl citrate; concomitant therapy, 770
Fentanyl; dosage; transdermal pain therapy, 718
Fertilization in vitro; midazolam hydrochloride; follicular fluid levels, 770
Filtration; ultra; effects, quinidine blood levels, 917
Finasteride; prostate hypertrophy; therapy, review, 15
Fluconazole
 product withdrawal; toxicity, 713
 toxicity; high dosage, clinical studies, 474
Flumazenil
 rational therapy; benzodiazepine overdose, overview, 691
 therapy; benzodiazepine overdose, review, 641; respiratory depression, benzodiazepine toxicity, 483
 use; evaluation, criteria, 536
Fluoxetine; premenstrual syndrome; therapy, psychological symptoms, 181
Food and Drug Administration (U.S.)
 approvals; accelerated, final regulations, 253; amiodipine marketing, 93; atovaquone marketing, 175; cisapride marketing, 876; cladribine marketing, 391;

enoxaparin marketing, 471; felbamate marketing, 713; itraconazole marketing, 6; loratadine marketing, 474; medroxyprogesterone marketing, 92; mesalamine marketing, 555; new drugs, evaluative reviews, need, 306; new drugs, 1992, 247; sotalol marketing, 176; strontium chloride Sr 89 marketing, 632; tacrine marketing, 873; teniposide marketing, 6; Tetramune marketing, 391
labeling; new regulations, nonprescription drugs, 800; proposed ruling, prescription, pediatrics, 6
MEDWatch; medical product reporting program, 529
Prescription Drug User Fee Act of 1992; laws, pharmaceutical industry, 3
regulations; clinical studies, women, 395; levomethadyl maintenance, narcotic treatment programs, 797; women, clinical studies, new drugs, 712
 stavudine; AIDS therapy, parallel track policy approvals, 7
unapproved drugs; regulations, imports, AIDS buyers' clubs, 632
Forms; reports; MEDWatch, FDA programs, 529
Formulations; quinacrine hydrochloride; pleurodesis solutions, pneumothorax therapy, 693
Eurosemide; toxicity; pancreatitis, review, 440

G

Gallium nitrate; hypercalcemia; therapy, malignancy-induced, review, 117
Gastroesophageal reflux; cisapride; therapy, FDA approvals, 876
Gastrointestinal drugs
 bisnuth; peptic ulcers, *H. pylori*, combined therapy, review, 34
 cisapride; marketing, FDA approvals, 876
 mesalamine; FDA approvals, 555
 metoclopramide; lactation stimulation, therapy, 479
Gene therapy
 cystic fibrosis; review, 657
 research; genetic disorders, neoplasms, review, 488
Genetic engineering; gene therapy; research, review, 488
Gentamicin; pharmacokinetics; prediction, vancomycin pharmacokinetics, 909
Gentamicin sulfate
 body distribution; pharmacokinetics, septic shock, 131
 pharmacokinetics; term newborn twins, 615
Geriatrics
 hypertension; systolic, therapy, review, 347; therapy, protocols, 53
 mexiletine; pharmacokinetics, age, effects, 768
 ticlopidine hydrochloride; toxicity, cholestasis, 398
 vancomycin; pharmacokinetics, 481
Ginseng; dietary supplements; athletes, ergogenic effects, 900
Glycerin; dosage forms; enemas vs. suppositories, neonates, 846
Globulin immune
 graft vs. host disease; prophylaxis, bone marrow transplantation, 736
 therapy; altered immunocompetence, ACIP, 675
Glomerulonephritis; therapy; membranoproliferative, review, 429
Glomerulosclerosis; therapy; focal, review, 429
Gonadorelin agonists; premenstrual syndrome; therapy, 181
Graft rejection
 cyclosporine; prophylaxis, DUE criteria, transplant recipients, 696
 muromonab-CD3; therapy, encephalopathy toxicity, 610
Graft vs. host disease; therapy; prophylaxis, bone marrow transplantation, 736
Grants; Agency for Health Care Policy and Research; pharmacists' role, health care, 474
Guidelines; National Institutes of Health; clinical studies, news media, alerts, 637
Guidelines, treatment, see **Protocols**

H

Haemophilus b oligosaccharide conjugate vaccines; combination, diphtheria and tetanus toxoids and pertussis vaccines; marketing, FDA approvals, 391
Haemophilus b polysaccharide conjugate vaccines; immunogenicity; low, list, 176
Half-life
 gentamicin sulfate; term newborn twins, 615
 vancomycin; pharmacokinetics, geriatrics, 481

vancomycin hydrochloride; pharmacokinetics, hematologic malignancy, 515

Haloperidol lactate; therapy; aggressive sex behavior, propofol toxicity, 449

HA-1A see **Nebacumab**

Hay fever; loratadine; therapy, FDA approvals, 474

Health care; pharmacists; role, grants, appropriate drug use, 474

Health professions

role; MEDWatch, FDA programs, 529

tuberculosis; surveillance programs, 167

Heart failure; flosequinan; congestive, high dose, toxicity, 474

Helicobacter infections; therapy; peptic ulcers, 34

Helicobacter pylori; therapy; peptic ulcers, review, 34

Hematologic diseases; vancomycin hydrochloride; neoplasms, pharmacokinetics, dosage, 515

Heparin

dose; estimation, pharmacokinetic models, 597
 low molecular weight; cerebrovascular disorders

therapy, review, 359

myocardial infarction; therapy, 197

Heparinoids; cerebrovascular disorders; therapy, review, 359

Heparins; thrombophlebitis; low-molecular-weight vs. unfractionated, 892

Histoplasmosis; itraconazole; therapy, FDA approvals, 6

HIV infections; protocols; altered immunocompetence, therapy, ACIP, 675

Hydrochlorothiazide; comparison, enalapril maleate, propranolol hydrochloride; effects, cognition, motor activity, quality of life, 300

Hyperalimentation, see **Nutrition; parenteral**

Hypercalcemia

gallium nitrate; therapy, malignancy-induced, review, 117

pamidronate disodium; therapy, malignancy-induced, review, 117

Hypernatremia; nutrition; parenteral, total, toxicity, 138

Hypertension

amlodipine besylate; therapy, FDA approvals, 93

enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; toxicity, quality of life, 300

felodipine; therapy, review, 261

hydrochlorothiazide, comparison, enalapril maleate, hydrochlorothiazide; toxicity, quality of life, 300

isradipine; therapy, review, 261

propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; toxicity, quality of life, 300

protocols; therapy, 53

therapy; systolic, geriatrics, review, 347

Hyperthyroidism; amiodarone; toxicity, 774

Hypoalbuminemia; albumin human; therapy, effects, serum protein levels, 377

Hyponatremia; nutrition; parenteral, total, toxicity, 138

Hypotensive agents

clonidine hydrochloride; maternal consumption, lactation, infant blood levels, 178

enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; effects, cognition and motor activity, quality of life, 300

felodipine; therapy, review, 261

hydrochlorothiazide, comparison, enalapril maleate, hydrochlorothiazide; effects, cognition and motor activity, quality of life, 300

isradipine; therapy, review, 261

propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; effects, cognition and motor activity, quality of life, 300

protocols; therapy, 53

Hypothyroidism; amiodarone; toxicity, 774

I

Iatrogenic diseases, see **Drugs, adverse reactions**

Immunization

diphtheria and tetanus toxoids and pertussis and *Haemophilus influenzae*; conjugate vaccines, pediatrics, FDA approvals, 391

Haemophilus influenzae; conjugate vaccines, low immunogenicity, list, 176

tuberculosis; BCG vaccines, health professions, surveillance programs, 167

vaccines; altered immunocompetence, ACIP protocols, 375

Immunoassay

enzyme multiplied; vs. fluorescence polarization, an-

tiarrhythmic agents, 49
fluorescence polarization; vs. enzyme multiplied, antiarrhythmic agents, 49

Immunocompetence; protocols; altered, globulin immune, immunization, ACIP, 675

Immunogenicity; *Haemophilus b* polysaccharide conjugate vaccines; low, list, 176

Immunologic deficiency syndromes; protocols; vaccines, globulin immune, ACIP, 675

Immunosuppression; vitamin A; immunomodulating effects, review, 506

Immunosuppressive agents

azathioprine; toxicity, pancreatitis, review, 440
cyclosporine; alone and with methotrexate, graft vs. host disease, marrow transplantation, 736; DUE criteria, transplant recipients, 696; nephrotic syndrome, review, 429
methotrexate; graft vs. host disease, marrow transplantation, 736

muromonab-CD3; toxicity, encephalopathy, graft resection therapy, 610
tacrolimus; graft vs. host disease, marrow transplantation, 736

thalidomide; graft vs. host disease, marrow transplantation, 736

Immunotherapy

antithymocyte globulin; graft vs. host disease, marrow transplantation, 736

globulin immune; graft vs. host disease, marrow transplantation, 736

molgramostim; side effects, bone marrow transplantation, 520

nebacumab; clinical studies, marketing, withdrawal, toxicity, 254

protocols; altered immunocompetence, ACIP, 675
sargramostim; agranulocytosis therapy, sulfasalazine toxicity, 179; dosage, 520

vitamin A; immunomodulating effects, review, 506
zolimomab artox; graft vs. host disease, marrow transplantation, 736

Imports; unapproved drugs; AIDS buyers' clubs, FDA regulations, 632

Indometacin; use; evaluation, criteria, neonates, 232

Industry, pharmaceutical

advertising; accelerated drug approvals, FDA regulations, 253

labeling; nonprescription drugs, FDA regulations, 800; prescription drugs, pediatrics, FDA ruling, 6
new-drug applications; clinical studies, women, FDA regulations, 712

Prescription Drug User Fee Act of 1992; laws, FDA approvals, 3

Infections; vitamin A; immunomodulating effects, review, 506

Injections

anthracyclines; extravasation, dimethyl sulfoxide therapy, 560

catheters; i.v. pressure, extravasation prediction, infants, 216

ciprofloxacin; intravenous therapy, infections, DUE criteria, 226

indomethacin; DUE criteria, neonates, 232

medroxyprogesterone acetate; marketing, FDA approvals, 92

Insomnia; zolpidem tartrate; therapy, review, 814

Interleukin inhibitors; shock; septic, therapy, review, 829

Iodine I 131; hyperthyroidism; therapy, amiodarone toxicity, 774

Isosorbide dinitrate; hypertension; systolic, therapy, geriatrics, review, 347

Isradipine; hypertension; therapy, review, 261

Itraconazole; marketing; FDA approvals, 6

J

Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure; reports; hypertension therapy, protocols, 53

Journals

American Journal of Hospital Pharmacy; merging, *Clinical Pharmacy*, 526, 923

Clinical Pharmacy; merging, *AJHP*, 526, 923

K

Kidney failure; temafloxacin hydrochloride; adverse reactions, hemolytic anemia, 380

L

Labeling

drugs, nonprescription; FDA regulations, 800
pediatrics; prescriptions, FDA proposed ruling, 6

Lactation

clonidine hydrochloride; maternal consumption, infant blood levels, 178
therapy; stimulation, 479

Laws; Prescription Drug User Fee Act of 1992; pharmaceutical industry, FDA approvals, 3

Letters, 13, 178, 255, 398, 481, 718, 802, 881

Clonidine and breast-feeding, 178

Comment on ASHP therapeutic guidelines, 399

Dosage of transdermal fentanyl, 718

Ketocazole and gastric acidity, 802

Long-term dobutamine therapy, 13

Pharmacokinetics of oxaprozin, 255

Prophylaxis with aztreonam plus metronidazole during appendectomy, 803

Recognition of severe cefixime-induced diarrhea, 881

Relative safety and efficacy of pravastatin, 256

Sargramostim for sulfasalazine-induced agranulocytosis, 179

Ticlopidine-induced cholestatic jaundice, 398

Use and safety of sumatriptan, 258

Vancomycin pharmacokinetics in elderly patients, 481

Leucovorin calcium; comparison, leucovorin calcium; equivalency, oral vs. i.v., availability, 293

Leukemia

cladribine; hairy cell, therapy, FDA approvals, 391
therapy, review, 805

teniposide; lymphocytic, therapy, FDA approvals, 6

Leucovorin calcium; comparison, leucovorin calcium; equivalency, oral vs. i.v., availability, 293

Levomephadyl acetate; therapy; maintenance, narcotic treatment programs, 797

Levothyroxine sodium; hypothyroidism; therapy, amiodarone toxicity, 774

Lidocaine hydrochloride; pharmacokinetics; monitoring, pharmacists' role, 527

Literature; new drugs; evaluative reviews, need, 306

Lithium; use; evaluation, criteria, 617

Lomefloxacin; use; evaluation, criteria, 452

Loratadine; marketing; FDA approvals, 474

M

Magnesium; myocardial infarction; therapy, mechanism of action, review, 588

Marketing

amlodipine besylate; FDA approvals, 93

atavouquone; FDA approvals, 175

cisapride; FDA approvals, 876

cladribine; FDA approvals, 391

diphtheria and tetanus toxoids and pertussis vaccines, combination; *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, 391

enoxaparin; FDA approvals, 471

felbamate; FDA approvals, 713

floquinace; product withdrawal, 713

itraconazole; FDA approvals, 6

loratadine; FDA approvals, 474

medroxyprogesterone acetate; FDA approvals, 92

mesalamine; FDA approvals, 555

nebacumab; clinical studies, withdrawal, toxicity, 254

new drugs; evaluative reviews, need, 306; FDA approval, 1992, 247

sotalol hydrochloride; FDA approvals, 176

strontium chloride Sr 89; FDA approvals, 632

tacrine hydrochloride; FDA approvals, 873

teniposide; FDA approvals, 6

Measles; vitamin A; immunomodulating effects, review, 506

MEDWatch; reports; FDA programs, 529

Mechanism of action

amiodarone; toxicity, thyroid dysfunction, 774

atavouquone; *P. carinii* pneumonia, therapy, review, 563

cladribine; leukemia therapy, review, 805

dimethyl sulfoxide; anthracycline extravasation therapy, 216

flumazenil; review, 641

magnesium; myocardial infarction therapy, review, 568

replacement solutions; resuscitation, review, 335

temafloxacin hydrochloride; adverse reactions, hemolytic anemia, 380

vitamin A; immunomodulating effects, review, 506

Medroxyprogesterone acetate; marketing; FDA approvals, 92

Meperidine hydrochloride; use; evaluation, criteria, patient-controlled analgesia, 150

Mercaptopurine; toxicity; pancreatitis, review, 440

Mesalamine; marketing; FDA approvals, 555

Methodology

clinical studies; women, FDA regulations, 712

creatinine; clearance, estimation, gynecologic neoplasms, 685

heparin; dosage estimation, pharmacokinetic models, 597

injections; i.v. pressure, extravasation prediction, infants, 216

phenytoin; unbound, blood levels prediction, equations, 913

quinidine; blood levels, effects, ultrafiltration, temperature, 917

vancomycin; pharmacokinetics, prediction, 909

vancomycin hydrochloride; dosage, calculations, computers, 126

Methotrexate

alone and with cyclosporine; graft vs. host disease, prophylaxis, marrow transplantation, 736

asthma; therapy, overview, 762

N-5-Methyltetrahydrofolate; blood levels; leucovorin; leucovorin generic equivalency, 293

Metoclopramide; lactation; stimulation, 479

Metronidazole

and aztreonam; colorectal surgery, prophylaxis, ASHP protocols, 399

diarrhea; therapy, ceftizoxime toxicity, 881

ulcers; peptic, combined therapy, *H. pylori*, review, 34

Mexiletine; pharmacokinetics; effects, age, geriatrics, 768

Midazolam hydrochloride; body distribution; follicular fluid levels, in vitro fertilization, 770

Minerals and vitamins; dietary supplements, athletes, ergogenic effects, 900

Models

heparin; pharmacokinetics, dosage estimation, 597

vancomycin; clearance, dosage calculations, 126

Mogamostin; toxicity; side effects, bone marrow transplantation, 520

Morphine sulfate; use; evaluation, criteria, patient-controlled analgesia, 150

Morphine; equivalency, therapeutic; fentanyl, transdermal dosage, 718

Mortality

anticoagulants; myocardial infarction therapy, 197

floquinace; high dose, toxicity, clinical studies, 474; toxicity, product withdrawal, 713

Motor activity

enalapril maleate, comparison, hydrochlorothiazide, propantheline, 300

hydrochlorothiazide, comparison, enalapril maleate, propantheline hydrochloride; toxicity, hypertension therapy, 300

propantheline hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; toxicity, hypertension therapy, 300

Mucolytic agents; cystic fibrosis; therapy, review, 657

Muromonab-CD3; toxicity; encephalopathy, graft resection therapy, 610

Mycobacterium tuberculosis; resistance; antituberculosis, health professions, surveillance programs, 167

Myocardial infarction

magnesium; therapy, mechanism of action, review, 588

therapy, 197

N

Nadroparin; thrombophlebitis; low-molecular-weight heparins vs. unfractionated, 892

National Institute of Allergy and Infectious Diseases; didanosine, comparison, zalcitabine; AIDS therapy, efficacy, clinical studies, 391

zalcitabine, comparison, didanosine; AIDS therapy, efficacy, clinical studies, 391

National Institutes of Health; guidelines; clinical studies, news media, alerts, 637

National Institute on Drug Abuse; regulations; levomethadyl maintenance, narcotic treatment programs, 797

Nausea; ondansetron hydrochloride; therapy, adverse reactions, seizures, 613

Nebacumab; clinical studies; and marketing withdrawal, toxicity, 254

Neoplasms

aldesleukin; therapy, DUE criteria, 853

creatinine; clearance, estimation, gynecologic neoplasms, 685
epoetin alfa; anemia therapy, DUE criteria, 925
gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117
gene therapy; research, review, 488
pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117
vancomycin hydrochloride; hematologic pharmacokinetics, dosage, 515
Nephritis; therapy; lipid, therapy, review, 429
Nephrotic syndrome; therapy; review, 429
News, 3, 91, 167, 247, 327, 391, 471, 551, 632, 712, 793, 873
Acyclovir should not be used routinely for chickenpox, says pediatrics academy, 175
AHA issues report on Kawasaki disease, 555
AHCP awards 14 grants for patient outcomes research, 474
American Heart Association updates life support guidelines, 171
Amlodipine approved for hypertension, angina therapy, 93
Atovaquone to be marketed as oral therapy for *Pneumocystis carinii* pneumonia, 175
Book correction notice, 637
CDC issues recommendations for rehydration and nutritional therapy for children with acute diarrhea, 92
CDC revises AIDS case definition, 254
Centocor suspends HA-1A testing, halts foreign sales, 254
Cisapride marketed for use in gastroesophageal reflux disease, 876
Cladribine approved as first-line therapy for hairy cell leukemia, 391
Combination vaccine approved for use in children, 391
Conference, reports address public-health implications of tuberculosis, 167
Consensus recommendations for antithrombotic therapy updated, 92
Continued use of chloral hydrate justified, concludes pediatrics academy, 876
Easier-to-use pирbuterol inhaler marketed, 715
FDA clears 26 new drugs for marketing in 1992, 247
FDA issues regulations on accelerated drug-approval process, 253
FDA plans policy change on inclusion of women in clinical trials, 395
FDA proposes more stringent pediatric-use labeling of prescription drug products, 6
FDA reiterates personal-use importation policy to buyers' clubs, 632
FDA user fees approved, 3
Flosequinan withdrawn from market, 713
Four-drug regimen, directly observed therapy urged for initial tuberculosis therapy, 793
Guidelines for release of clinical alerts set, 637
Higher folic acid intake could prevent many common birth defects, says pediatrics academy, 879
Intensive care units see increase in resistant enterococci, 797
Itraconazole released for blastomycosis and histoplasmosis therapy, 6
I.V. antimicrobials not indicated for presumed Lyme disease, say rheumatology, infectious diseases groups, 876
Levomethadyl acetate to be used in narcotic treatment programs, 797
Low-molecular-weight heparin to be marketed, 471
Medroxyprogesterone acetate granted contraceptive indication in U.S., 92
New antiepilepsy drug, felbamate, marketed, 713
New FDA policy encourages inclusion of women in clinical trials, 712
News Briefs, 7, 93, 176, 254, 331, 395, 474, 555, 637, 715, 879
Nonionic contrast medium for MRI procedures marketed, 93
Nonsedating antihistamine approved by FDA, 474
Nutrition support guidelines published, 715
Oral mesalamine formulation to be marketed, 555
Patient deaths halt fluridilide trials, 715
Pediatrics academy releases guidelines for prevention of neonatal group B streptococcal infection, 91
Physician group releases guidelines on preventive hormonal therapy, 327
Preliminary data show mortality risk from high-dose flosequinan, 474
Preliminary study analysis suggests similar efficacy for didanosine and zalcitabine, 391
Preliminary study findings fuel debate over timing of zidovudine therapy, 551
Public Health Service issues recommendations for

prophylaxis against *Mycobacterium avium* complex, 797

Radiopharmaceutical approved for relief of pain caused by bone metastases, 632

Sixteen PedvaxHIB vaccine lots have low immunogenicity, 176

Sotalol marketed for life-threatening arrhythmias, 176

Stavudine made available under parallel track policy, 7

Study provides additional support for warfarin use by patients with atrial fibrillation, 93

Study shows deleterious effects from digoxin withdrawal, 713

Study shows diazepam use during febrile illnesses reduces risk of recurrent febrile seizures, 800

Surveillance study adds to database on seroconversion rates and zidovudine use after occupational exposures, 636

Tacrine granted marketing approval for Alzheimer's disease, 873

Teniposide granted marketing approval, 6

Three categories of nonprescription drug products to carry new warnings, 800

Upcoming Specialty Meetings, 7, 93, 254, 331, 395, 475, 558, 637, 800, 879

News media: clinical studies; clinical alerts, NIH guidelines, 637

Nifedipine: toxicity; bezoars, sustained-action tablets, 849

Nomograms: phenytoin; dosage, unbound, blood levels prediction, 913

vancomycin hydrochloride; initial dosage schedules, hematologic malignancy, 515

Nutrition: diet; and supplements, athletes, review, 900

parenteral; N-acetyl-L-tyrosine, excretion, infants, 606; albumin effects, serum protein levels, hypoalbuminemia, 577; total, toxicity, sodium disorders, 138

support; respiratory tract diseases, review, 276

O

Octacosanol: dietary supplements; athletes, ergogenic effects, 900

Ofloxacin: use; evaluation, criteria, 452

Ondansetron hydrochloride: adverse reactions; seizures, nausea therapy, 613

Opiates: levomethadyl acetate; maintenance therapy, narcotic treatment programs, 797

Organizations: American Society of Hospital Pharmacists; AHP, Clinical Pharmacy, merging, 526, 923

Ovarian neoplasms: paclitaxel; refractory, therapy, review, 401

Oxygen radical scavengers: dimethyl sulfoxide; anthracine extravasation therapy, 560

P

Paclitaxel: ovarian neoplasms; refractory, therapy, review, 401

Pain:

anti-inflammatory agents; nonsteroidal, long-term therapy, DUE criteria, 780

fentanyl; transdermal therapy, dosage, 718

patient-controlled analgesia; therapy, DUE criteria, 150

strontium chloride Sr 89; therapy, bone neoplasms, FDA approvals, 632

Pamidronate disodium: hypercalcemia; therapy, malignancy-induced, review, 117

Pancreatitis:

asparaginase; toxicity, review, 440

azathioprine; toxicity, review, 440

danazol; toxicity, review, 440

estrogens; toxicity, review, 440

furosemide; toxicity, review, 440

mercaptopurine; toxicity, review, 440

pentamidine; toxicity, review, 440

sulfonamides; toxicity, review, 440

sunlida; toxicity, review, 440

tetracyclines; toxicity, review, 440

thiazides; toxicity, review, 440

valproic acid; toxicity, review, 440

Parenterals, see **Injections**

Patches transdermal: fentanyl; dosage, pain therapy, 718

Patient-controlled analgesia: protocols; DUE criteria, 150

Patients

drugs, personal; unapproved, imports, AIDS buyers' clubs, FDA regulations, 632

inpatients; lithium, DUE criteria, 617; lomefloxacin, ofloxacin, DUE criteria, 452; NSAIDs, DUE criteria, 780; ticlopidine, DUE criteria, 64; warfarin, DUE criteria, 307

outpatients; flumazenil, DUE criteria, 536; lithium, DUE criteria, 617; lomefloxacin, ofloxacin, DUE criteria, 452; NSAIDs, DUE criteria, 780; ticlopidine, DUE criteria, 64; warfarin, DUE criteria, 307

Pediatrics

N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606

acyclovir; chickenpox therapy, AAP recommendations, 175

bronchiolitis; therapy, review, 95

chloral hydrate; AAP recommendations, 876

clonidine hydrochloride; maternal consumption, lactation, infant blood levels, 178

diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; immunization, FDA approvals, 391

Haemophilus b polysaccharide conjugate vaccines; low immunogenicity, list, 176

injections; I.V. pressure, catheter extravasation prediction, infants, 216

neonates; gentamicin pharmacokinetics, term newborn twins, 615; glycerin enemas vs. suppositories, 846; indomethacin injections, DUE criteria, 232 prescriptions; labeling, FDA proposed ruling, 6

teniposide; lymphocytic leukemia therapy, FDA approvals, 6

Penicillins: amoxicillin; peptic ulcers, *H. pylori*, combined therapy, review, 34

Pentamidine: toxicity; pancreatitis, review, 440

Peritonitis: dialysis; peritoneal, effects, α -acid glycoprotein concentrations, 602

Pharmacists: role; health care, grants, 474; lidocaine, pharmacokinetics monitoring, 527

Pharmaceutical care: American Society of Hospital Pharmacists; journals, merging, 923

Pharmaceutical services: research; grants, appropriate drug use, 474

Pharmacodynamics: atovaquone; *P. carinii* pneumonia, therapy, review, 563

Pharmacokinetics

N-acetyl-L-tyrosine; excretion, infants, parenteral nutrition, 606

aminoglycosides; body distribution, septic shock, 131; prediction, vancomycin pharmacokinetics, 909

amlodipine besylate, 93

atavoquone, 175; *P. carinii* pneumonia, therapy, review, 563

cefepime; cholecystectomy, acute cholecystitis, 134

cladribine, 391; leukemia therapy, review, 805

enoxaparin, 471

felbamate, 713

felodipine; hypertension therapy, review, 261

finasteride; prostatic hypertrophy therapy, review, 15

flumazenil; review, 641

gentamicin sulfate; term newborn twins, 615

heparin; models, dosage estimation, 597

isradipine; hypertension therapy, review, 261

itraconazole, 6

lidocaine hydrochloride; monitoring, pharmacists' role, 527

loratadine, 474

medroxyprogesterone acetate, 92

mesalamine, 555

melexetine; effects, age, geriatrics, 768

paclitaxel; refractory ovarian neoplasms therapy, review, 401

sotalol hydrochloride, 176; arrhythmia therapy, review, 883

strontium chloride Sr 89, 632

tacrine hydrochloride, 873

teniposide, 6

vancomycin; geriatrics, 481; prediction, aminoglycoside pharmacokinetics, 909

vancomycin hydrochloride; dosage, hematologic malignancy, 515

zolpidem tartrate; insomnia therapy, review, 814

Pharmacy and therapeutics committee: new drugs; decisions, evaluative reviews, need, 306

Pharmacy, institutional, hospital: quality assurance programs, aldesleukin, DUE criteria, 853; programs, ciprofloxacin, DUE criteria, 226; programs, cycloserine, DUE criteria, 696; programs, epoetin alfa DUE criteria, 925; programs, flumazenil DUE criteria, 536; programs, indomethacin injections, DUE criteria, neonates, 232; programs, lithium DUE criteria, 617; pro-

grams, lomefloxacin, ofloxacin, DUE criteria, 452; programs, NSAIDs, DUE criteria, 780; programs, patient-controlled analgesia, DUE criteria, 150; programs, ticlopidine DUE criteria, 64; programs, warfarin DUE criteria, 307

Pharmacy, institutional; new drugs; evaluative reviews, need, 306

Phenytoin; blood levels; prediction, equations, unbound concentration, 913

Photosensitivity; drugs; toxicity, review, 580

Placental transfer; procainamide hydrochloride; lack, neonates, 58

Platelet aggregation inhibitors; glomerulonephritis; membranoproliferative, therapy, review, 429

ticlopidine; DUE criteria, 64

Pneumonia; atovaquone; *P. carinii*, therapy, FDA approvals, 175; *P. carinii*, therapy, review, 563

Pneumothorax; quinacrine hydrochloride; therapy, pleurodesis solution, cystic fibrosis, 693

Polympyalgia rheumatica; therapy; review, 571

Postmarketing surveillance; drugs, adverse reactions; MEDWatch, FDA programs, 529

regulations; FDA accelerated drug approvals, 253

Prednisolone; polymyalgia rheumatica; therapy, review, 571

Prednisone; aspergillosis; allergic bronchopulmonary, therapy, review, 24

polymyalgia rheumatica; therapy, review, 571

Pregnancy; procainamide hydrochloride; side effects, lack, 58

Premenstrual syndrome; therapy; review, 181

Prescription Drug User Fee Act of 1992; laws; pharmaceutical industry, FDA approvals, 3

Prescriptions; drugs; appropriate use, grants, pharmacists' role, 474; pediatric labeling, FDA proposed ruling, 6

Pressure; catheters; extravasation prediction, infants, 216

Procainamide; blood levels; fluorescence polarization methods, 49

Procaainamide hydrochloride; toxicity; side effects, lack, pregnancy, 58

Product withdrawal; flesequinol; toxicity, high dose, 713

nebacumab; foreign market, toxicity, 254

Professional fees; new-drug applications; Prescription Drug User Fee Act of 1992, pharmaceutical industry, 3

Progesterone; premenstrual syndrome; therapy, 181

Progesterins; progesterone; premenstrual syndrome therapy, 181

Propofol; toxicity; aggressive sex behavior, 449

Propranolol hydrochloride; comparison, enalapril maleate, hydrochlorothiazide; effects, cognition, motor activity, quality of life, 300

Propylthiouracil; hyperthyroidism; therapy, amiodarone toxicity, 774

Prostaglandin inhibitors; premenstrual syndrome; therapy, 181

Prostatic hypertrophy; finasteride; therapy, review, 15

Prontostat; ciprofloxacin; therapy, DUE criteria, 226

Protocols; acyclovir; chickenpox therapy, AAP recommendations, 175

aldesleukin; DUE criteria, 853

American Society of Hospital Pharmacists; antimicrobial prophylaxis, colorectal surgery, 399

anti-inflammatory agents; nonsteroidal, DUE criteria, 780

chloral hydrate; pediatrics, AAP recommendations, 876

ciprofloxacin; DUE criteria, 226

cyclosporine; DUE criteria, transplant recipients, 696

epoetin alfa; DUE criteria, 925

flumazenil; DUE criteria, 536

hypotensive agents; therapy, 53

immunization; vaccines, altered immunocompetence, ACIP, 675

immunotherapy; altered immunocompetence, ACIP, 675

indomethacin; injections, DUE criteria, neonates, 232

lidocaine hydrochloride; dosage, pharmacokinetics monitoring, pharmacists' role, 527

lithium; DUE criteria, 617

lomefloxacin; DUE criteria, 452

ofloxacin; DUE criteria, 452

patient-controlled analgesia; DUE criteria, 150

stavudine; AIDS buyers' clubs; parallel track policy, FDA approvals, 7

ticlopidine; DUE criteria, 64

warfarin; DUE criteria, 307

Publications

American Society of Hospital Pharmacists; *AJHP, Clinical Pharmacy*, merging, 526, 923
new drugs; evaluative reviews, need, 306

Purchasing; unapproved drugs; AIDS buyers' clubs, FDA regulations, 632

Q

Quality assurance; hospital pharmacy; programs, aldesleukin DUE criteria, 853; programs, ciprofloxacin, DUE criteria, 226; programs, cyclosporine DUE criteria, 696; programs, DUE criteria, 64; programs, epoetin alfa DUE criteria, 925; programs, flumazenil; DUE criteria, 536; programs, indomethacin injections, DUE criteria, neonates, 232; programs, lithium DUE criteria, 617; programs, lomefloxacin, ofloxacin, DUE criteria, 452; programs, NSAIDs, DUE criteria, 780; programs, patient-controlled analgesia, DUE criteria, 150; programs, warfarin DUE criteria, 307

Quality of life; enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; cognition and motor activity, effects; hypertension therapy, 300

hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; cognition and motor activity, effects; hypertension therapy, 300

propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; cognition and motor activity, effects; hypertension therapy, 300

Quinacrine hydrochloride; pneumothorax; therapy, pleurodesis solution, cystic fibrosis, 693

Quinidine; binding; plasma, effects, ultrafiltration, 917

blood levels; fluorescence polarization vs. EMIT, 49

Quinolones; ciprofloxacin; DUE criteria, 226

lomefloxacin; DUE criteria, 452

ofloxacin; DUE criteria, 452

photosensitivity; toxicity, review, 580

temafloxacin hydrochloride; adverse reactions, hemolytic anemia, 380

R

Radiopharmaceuticals; strontium chloride Sr 89; FDA approvals, 632

Rational therapy; acyclovir; chickenpox, AAP recommendations, 175

fentanyl; transdermal pain therapy, morphine replacement, 718

flumazenil; benzodiazepine overdose, overview, 691

nutrition; parenteral, monitoring, serum protein levels, hypoalbuminemia, 377

research; pharmacy, grants, 474

Regulations; clinical studies; women, gender-related differences, 395

Food and Drug Administration; labeling, nonprescription drugs, 800; prescriptions, labeling, pediatrics, 6; unapproved drugs, imports, AIDS buyers' clubs, 632; women, clinical studies, new drugs, 712

levomethadyl acetate; maintenance, narcotic treatment programs, 797

new-drug applications; accelerated, FDA approvals, 253

Replacement solutions; albumin human; effects, serum protein levels, parenteral nutrition, 377

resuscitation; clinical studies, review, 415; selection, clinical studies, review, 335

Reports; drugs, adverse reactions; MEDWatch, FDA programs, 529

hypertension; therapy, protocols, 53

Research; gene therapy; genetic disorders, neoplasms, review, 488

pharmacy; grants, appropriate drug use, 474

Resistance; antituberculars; *M. tuberculosis*, health professions, surveillance programs, 167

Respiratory tract diseases; nutrition; therapy, review, 276

Resuscitation; replacement solutions; clinical studies, review, 415; selection, clinical studies, review, 335

Ribavirin; bronchiolitis; therapy, pediatrics, review, 95

Ringer's injection lactated; replacement solutions; selection, clinical studies, review, 335

S

Sargamostim

agranulocytosis; therapy, sulfasalazine toxicity, 179

comparison, molgramostim; dosage, 520

Sclerosing agents; quinacrine hydrochloride; pneumothorax therapy, pleurodesis solutions, cystic fibrosis, 693

Seizures

ondansetron hydrochloride; adverse reactions, nausea therapy, 613

Self-study Materials

243, 548

Concepts in Immunology and Immunotherapeutics, Second Edition, 243

Pharmacotherapy Self-Assessment Program: Module 1, Cardiovascular

Pharmacotherapy Self-Assessment Program: Module 2, Infectious Diseases, 548

Sertraline hydrochloride;

interactions; tranylcypromine, serotonergic syndrome, 222

Sex behavior;

propofol; aggressive, toxicity, 449

Sex

clinical studies; women, FDA regulations, 395

patients; effects, lack, heparin dosage estimation, 597

Shock

aminoglycosides; septic, body distribution, 131

therapy; septic, biotechnology, review, 829

Smoking;

effects; heparin dosage estimation, 597

Sodium chloride

injections; replacement solutions, selection, clinical studies, review, 335

replacement solutions; clinical studies, review, 415

Solutions;

quinacrine hydrochloride; pleurodesis, pneumothorax therapy, 693

Sotalol hydrochloride

arrhythmia; therapy, review, 883

marketing; FDA approvals, 176

Starches;

replacement solutions; selection, clinical studies, review, 335

Stavudine;

acquired immunodeficiency syndrome; therapy, parallel track policy, FDA approvals, 7

Steroids, cortico-

asthma; dependent, methotrexate therapy, overview, 762

cystic fibrosis; therapy, review, 657

graft vs. host disease; prophylaxis, bone marrow transplantation, 736

nephrotic syndrome; therapy, review, 429

prednisolone; polymyalgia rheumatica therapy, review, 571

prednisone; allergic bronchopulmonary aspergillosis therapy, review, 24; polymyalgia rheumatica therapy, review, 571

Storage; cladrubine; leukemia therapy, review, 805

Srontium chloride Sr 89; marketing; FDA approvals, 632

Sulfasalazine; toxicity; agranulocytosis, sargamostim therapy, 179

Sulfonamides; sulfasalazine; toxicity, agranulocytosis, sargamostim therapy, 179

Toxicity; pancreatitis, review, 440

Sulindac; toxicity; pancreatitis, review, 440

Suppositories; glycerin; vs. enemas, neonates, 846

Surgery

aminoglycosides; postoperative septic shock, body distribution, 131

anti-infective agents; colorectal, prophylaxis, ASHP protocols, 399

cefeprimes; pharmacokinetics, cholecystectomy, acute cholecystitis, 134

enoxaparin; thrombosis prophylaxis, FDA approvals, 471

epoetin alfa; anemia therapy, neoplasms, DUE criteria, 925

patient-controlled analgesia; posoperative pain, DUE criteria, 150

Sustained-action medications

mesalamine; oral marketing, FDA approvals, 555

nifedipine; toxicity, bezoars, 849

Sympatholytic agents; β blockers; atrial fibrillation, atrial flutter therapy, 721; hypertension therapy, protocols, 53; systolic hypertension therapy, geriatrics, review, 347

Sympathomimetic agents; β agonists; bronchitis, aerosols, therapy, pediatrics, review, 95; cystic fibrosis therapy, review, 657

T

Tablets

nifedipine; sustained-action, bezoars, toxicity, 849

quinacrine hydrochloride; formulations, pleurodesis solutions, pneumothorax therapy, 693

Tacrine hydrochloride; marketing; FDA approvals, 873

Tacrolimus; graft vs. host disease; prophylaxis, bone marrow transplantation, 736

Tamoxifen; premenstrual syndrome; therapy, mastodynia, 181

Temafloxacin hydrochloride; adverse reactions; hemolytic anemia; kidney failure, 380

Temperature; quinidine; effects, blood levels, ultrafiltration, 917

Teratogenicity; procainamide hydrochloride; pregnancy, 58

Tetracycline; bismuth and metronidazole; peptic ulcer therapy, *H. pylori*, review, 34

Tetracyclines

- photosensitivity; toxicity, review, 580
- tetracycline; peptic ulcers, *H. pylori*, combined therapy, review, 34
- toxicity; pancreatitis, review, 440

Tetrahydrofolic acid; blood levels; leucovorin-levoleucovorin generic equivalency, 293

Tetramune; diphtheria and tetanus toxoids and pertussis vaccines; combination, *Haemophilus b* oligosaccharide conjugate vaccines, 391

Thalidomide; graft vs. host disease; prophylaxis, bone marrow transplantation, 736

Theophylline; cystic fibrosis; therapy, review, 657

Therapy Consultation, 479, 560

- Dimethyl sulfoxide for treating anthracycline extravasation, 560
- Increasing breast milk supply, 479

Thiazides

- hypertension; systolic, therapy, geriatrics, review, 347
- photosensitivity; adverse reactions, review, 580
- toxicity; pancreatitis, review, 440

Thromboembolism; warfarin; prophylaxis, DUE criteria, 307

Thrombolytic agents; cerebrovascular disorders; therapy, review, 359

Thrombophlebitis; heparins; low-molecular-weight vs. unfractionated, 892

Thrombosis; enoxaparin; prophylaxis, FDA approvals, 471

Thyroid drugs; levothyroxine sodium; hypothyroidism therapy, 774

Ticlopidine hydrochloride; toxicity; cholestasis, 398

Ticlopidine; use; evaluation, criteria, 64

Tinzaparin; thrombophlebitis; low-molecular-weight heparins vs. unfractionated, 892

Tobramycin sulfate; body distribution; pharmacokinetics, septic shock, 131

Tobramycin; pharmacokinetics; prediction, vancomycin pharmacokinetics, 909

Toxicity

- see also Drugs, adverse reactions
- aldesleukin; DUE criteria, 853
- amiodarone; thyroid dysfunction, therapy, 774
- amlodipine besylate; side effects, 93
- anthracyclines; extravasation, dimethyl sulfoxide therapy, 560
- antiarrhythmic agents; side effects, 721
- anti-inflammatory agents; nonsteroidal, DUE criteria, 780
- antineoplastic agents; anemia, epoetin alfa therapy, DUE criteria, 925
- asparaginase; pancreatitis, review, 440
- atavouzole; side effects, 175; side effects, *P. carinii* pneumonia therapy, review, 563
- azathioprine; pancreatitis, review, 440
- benzodiazepines; flumazenil-use criteria, 536; overdose, flumazenil therapy, overview, 691; overdose, flumazenil therapy, review, 641; respiratory depression, flumazenil therapy, 483
- cefimezine; diarrhea, metronidazole therapy, 881
- chloral hydrate; carcinogenicity, lack, 876
- ciprofloxacin; DUE criteria, 226
- cisapride, 876
- cladribine, 391; side effects, leukemia therapy, review, 805
- clonidine hydrochloride; side effects, lack, lactation, infants, 178
- cyclosporine; DUE criteria, transplant recipients, 696
- didanosine; pancreatitis, review, 440
- didanosine, comparison, zalcitabine; side effects, AIDS therapy, NIAID clinical studies, 391
- dietary supplements; excessive proteins, 900
- diphtheria and tetanus toxoids and pertussis vaccines, combination, *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, marketing, 391
- drugs; photosensitivity, review, 580
- enalapril maleate, comparison, hydrochlorothiazide, propranolol hydrochloride; effects, cognition and motor activity, quality of life, 300
- exenatide, 471
- epoetin alfa; DUE criteria, 925
- estrogens; pancreatitis, review, 440
- felbamate; side effects, 713
- felodipine; side effects, hypertension therapy, review, 261
- fentanyl; inappropriate dosage recommendations, manufacturer, 718
- finasteride; side effects, prostatic hypertrophy therapy, review, 15
- flosequiquan; high dose, increased mortality, clinical studies, 474; side effects, product withdrawal, 713
- flumazenil; DUE criteria, 536; review, 641
- furosemide; pancreatitis, review, 440
- gallium nitrate; hypercalcemia therapy, malignancy-induced, review, 117
- glycerin; enemas vs. suppositories, neonates, 846
- heparins; low-molecular-weight vs. unfractionated, side effects, 892
- hydrochlorothiazide, comparison, enalapril maleate, propranolol hydrochloride; effects, cognition and motor activity, quality of life, 300
- indometacin; injections, DUE criteria, neonates, 232
- injections; extravasation, prediction, i.v. pressure, infants, 216
- isradipine; side effects, hypertension therapy, review, 261
- itraconazole; side effects, 6
- lidocaine hydrochloride; monitoring, pharmacists' role, 527
- lithium; DUE criteria, 617
- lomefloxacin; DUE criteria, 452
- loratadine, 474
- medroxyprogesterone acetate; side effects, 92
- meperidine hydrochloride; patient-controlled analgesia, DUE criteria, 150
- mercaptopurine; pancreatitis, review, 440
- mesalamine, 555
- methotrexate; side effects, asthma therapy, overview, 762
- molgramostim; side effects, bone marrow transplantation, 520
- morphine sulfate; patient-controlled analgesia, DUE criteria, 150
- muromonab-CD3; encephalopathy, graft rejection therapy, 610
- nebucabam; clinical studies, marketing, withdrawal, 254
- nifedipine; bezoars, sustained-action tablets, 849
- nutrition; parenteral, total, sodium disorders, 138
- ofloxacin; DUE criteria, 452
- paclitaxel; side effects, refractory ovarian neoplasms therapy, review, 401
- pamidronate disodium; hypercalcemia therapy, malignancy-induced, review, 117
- pentamidine; pancreatitis, review, 440
- procainamide hydrochloride; side effects, lack, pregnancy, 58
- propofol; aggressive sex behavior, 449
- propranolol hydrochloride, comparison, enalapril maleate, hydrochlorothiazide; effects, cognition and motor activity, quality of life, 300
- quinacrine hydrochloride; side effects, pleurodesis solutions, 693
- replacement solutions; review, 335
- sertraline hydrochloride; interactions, tranylcypromine, serotoninergic syndrome, 222
- solatol hydrochloride; side effects, 883; side effects, 176
- strontium chloride Sr 89, 632
- sulfasalazine; agranulocytosis, sargramostim therapy, 179
- sulfonamides; pancreatitis, review, 440
- sulindac; pancreatitis, review, 440
- tacrine hydrochloride, 873
- teniposide; side effects, 6
- tetracyclines; pancreatitis, review, 440
- thiazides; pancreatitis, review, 440
- ticlopidine; DUE criteria, 64
- ticlopidine hydrochloride; cholestasis, 398
- tranylcypromine sulfate; interactions, sertraline, serotoninergic syndrome, 222
- valproic acid; pancreatitis, review, 440
- warfarin; DUE criteria, 307

Transfection; gene therapy; research, review, 488

Transplantation

- bone marrow; homologous, graft vs. host disease, prophylaxis, 736; molgramostim toxicity, 520
- organs; cyclosporine, DUE criteria, 696

Tranlycypromine sulfate; interactions; sertraline, serotoninergic syndrome, 222

Trauma; replacement solutions; head, resuscitation, clinical studies, review, 415

Tuberculosis; Interscience Conference on Antimicrobial Agents and Chemotherapy; surveillance programs, health professions, immunization, 167

Tumor necrosis factor- α inhibitors; shock; septic, therapy, review, 829

U

Ulcers

- amoxicillin; peptic, *H. pylori*, combined therapy, review, 34
- bismuth; peptic, *H. pylori*, combined therapy, review, 34
- metronidazole; peptic, *H. pylori*, combined therapy, review, 34
- tetracycline; peptic, *H. pylori*, combined therapy, review, 34

United States Public Health Service; Advisory Committee on Immunization Practices; protocols, vaccines, immune globulin, altered immunocompetence, 675

Urinary tract infections

- ciprofloxacin; therapy, DUE criteria, 226
- lomefloxacin; therapy, DUE criteria, 452
- ofloxacin; therapy, DUE criteria, 452

V

Vaccines

- BCG; immunization, tuberculosis, surveillance programs, 167
- diphtheria and tetanus toxoids and pertussis vaccines; combination, *Haemophilus b* oligosaccharide conjugate vaccines; FDA approvals, marketing, 391
- Haemophilus b* polysaccharide conjugate; low immunogenicity, list, 176
- immunization; altered immunocompetence, ACIP protocols, 675

Valproic acid; toxicity; pancreatitis, review, 440

Vancomycin; pharmacokinetics; geriatrics, 481; prediction, aminoglycoside pharmacokinetics, 909

Vancomycin hydrochloride

- dosage; calculations, computers, 126
- pharmacokinetics; dosage, hematologic malignancy, 515

Vitamin A; mechanism of action; immunomodulating effects, review, 506

Vitamins

- and minerals; dietary supplements, athletes, ergogenic effects, 900
- supplements; cystic fibrosis therapy, review, 657
- vitamin A; mechanism of action, immunomodulating effects, review, 506

Volume of distribution, see Drugs, body distribution

W

Warfarin

- atrial fibrillation; therapy, 721
- myocardial infarction; therapy, 197
- use; evaluation, criteria, 307

Warfarin anticoagulants; warfarin; DUE criteria, 307

Weight; patients; effects, heparin dosage estimation, 597

Women; clinical studies; gender-related differences, FDA regulations, 395; new drugs, FDA regulations, 712

Writing; review; drugs, articles, 306

Z

Zalcitabine; comparison, didanosine; AIDS therapy, efficacy, NIAID clinical studies, 391

Zolimomab artox; graft vs. host disease; prophylaxis, bone marrow transplantation, 736

Zolpidem tartrate; insomnia; therapy, review, 814

Author Index

A

Adamson, Robert T. Book review, 864
 Adir, Joseph S. see Oparaoji, Edward C., 131
 Alaniz, Cesar Pharmacologic management of adult idiopathic nephrotic syndrome, 429
 Allen, Jill E. Drug-induced photosensitivity, 580
 Allen, Nancy M. Procainamide administration during pregnancy, 58
 Alsop, Judith Book review, 627
 Anderson, John R. see Zeisler, John A., Jr., 527
 Anderson, Philip O. Increasing breast milk supply (Therapy Consultation), 479
 Andersson, Borje S. see Ippoliti, Cindy, 520
 Annett, Miriam P. see McCrory, Eddie Jr., 300
 Artymowicz, Richard J. Atovaquone: a new antipneumocystis agent, 563
 Ateshkadi, Arasb *Helicobacter pylori* and peptic ulcer disease, 34
 Ateshkadi, Arasb see also Boheneck, Wayne S., 602

B

Baltz, Julie K. Cladribine for the treatment of hematologic malignancies, 805
 Bandettini, Francis C. see Bhataria, Vinod S., 222
 Barron, Richard L. Criteria for use of aldesleukin in adults, 853
 Barron, Richard L. Pathophysiology of septic shock and implications for therapy, 829
 Bashaw, E. Dennis see Hale, Victoria G., 255
 Bastide, Pierre see Chopineau, Jean, 770
 Bazin, Jean-Etienne see Chopineau, Jean, 770
 Bedikian, Annet see Okamoto, Mark P., 134
 Beltz, Susan Duran Efficacy of nutritional supplements used by athletes, 900
 Bennett, Teresa A. Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients, 925
 Berchou, Richard C. Book review, 242, 467
 Berne, Thomas V. see Okamoto, Mark P., 134
 Bhataria, Vinod S. Possible interaction between sertaline and tranylcypromine, 222
 Binkley, Jeffrey F. Effects of human albumin administration on visceral protein markers in patients receiving parenteral nutrition, 377
 Blanchard, Nick Book review, 787
 Bloom, Elana J. see Schwinghammer, Terry L., 736
 Bobo, Don Jr. see Phelps, Stephanie J., 216
 Boehm, Kristi A. see Christensen, Michael L., 606
 Boh, Larry E. see Lestico, Mitchell R., 571
 Boheneck, Wayne S. Effect of peritonitis on plasma and dialysate α_2 -acid glycoprotein concentrations in peritoneal dialysis patients, 602
 Borchardt-Phelps, Pamela K. Book review, 76
 Bottorff, Michael see Joch, Lois E., 597
 Brosius, Frank C. III see Alanz, Cesar, 429
 Brown, Rex O. see Binkley, Jeffrey F., 377
 Brown, Rex O. see also Mowatt-Larsen, Christine A., 276
 Bunjes, R. Clonidine and breast-feeding (letter), 178
 Bur, J. Michael see Renfro, William H., 232

C

Caballero, Dolores see Fernández de Gatta, María del Mar, 515
 Calis, Karim Anton see Goldspiel, Barry R., 488
 Canaday, Bruce R. Amorous, disinhibited behavior associated with propofol, 449
 Cannon, Miriam A. see Pavlov, Matthew J., 13
 Cantar, Kimberly A. see Jungnickel, Paul W., 257
 Cantú, Thomas G. see Goemann, Marti, 802
 Carter, Barry L. Current recommendations of the joint national high blood pressure committee, 53
 Carter, Barry L. see also Furmaga, Elaine M., 347
 Centers for Disease Control and Prevention Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence, 675
 Champlin, Richard E. see Ippoliti, Cindy, 520
 Chan, Frances A. see Sargent, Andrea L., 613
 Chandler, Mary H. H. see Rhoney, Denise H., 913
 Chandler, Mary H. H. see also Tsuaki, Tsuneo, 685
 Chandler, Mary H. H. see also Welch, Laura P., 909

Cheong, Ronnie Lum see Oparaoji, Edward C., 131
 Chin, Alfred see Okamoto, Mark P., 134
 Chopineau, Jean Assay for midazolam in liquor folliculi during in vitro fertilization under anesthesia, 770
 Chow, Moses S. S. see Fan, Chengde, 917
 Chow, Moses see also Kerland, Heather, 244
 Christensen, Michael L. Clearance of N-acetyl-L-tyrosine in infants receiving a pediatric amino acid solution, 606
 Cookson, Thomas L. see Ito, Matthew K., 126
 Cornish, Laura A. see Shaheen, Barbara E., 588
 Cornwell, Edward E. III see Oparaoji, Edward C., 131
 Côté, Daniel Dosage of transdermal fentanyl (letter), 718
 Culbert, James P. see McCrory, Eddie Jr., 300
 Cziraky, Mark J. Low-molecular-weight heparins for the treatment of deep-vein thrombosis, 892

D

D'Amato, Steven see Fraser, Gilles L., 481
 D'Amelio, Louis F. see Wagner, Bertil K. J., 335, 415
 Danziger, Larry H. Prophylaxis with aztreonam plus metronidazole during appendectomy (letter), 803
 Davis, Sharon K. see Ninno, Mark A., 696
 Deamer, Robert L. Temafloxacin-induced hemolytic anemia and renal failure, 380
 Deisseroth, Albert B. see Ippoliti, Cindy, 520
 DeLisa, Anna F. see Gregory, R. Elizabeth, 401
 Deppe, Scott A. see Sargent, Andrea L., 613
 DeVito, Joseph M. Bioequivalence of oral and injectable levoleucovorin and leucovorin, 293
 DiPiro, Joseph T. Book review, 933
 Doering, Paul L. see Beltz, Susan Durden, 900
 Dole, Ernest J. Book review, 704
 Dominguez-Gil Huré, Alfonso see Fernández de Gatta, María del Mar, 515
 Donnelly, Andrew J. Book review, 241
 Dreyfus-Vigil, Susan D. see Ito, Matthew K., 126
 Duc, Thomas A. see Michael, Katherine A., 150
 Duren, Lars L. see Ito, Matthew K., 126

E

Engel, Lisa M. see Rospond, Raylene M., 560
 Englander, Frank A. see Shalansky, Stephen J., 483
 Ezell, Jeanne R. see Marken, Patricia A., 617

F

Fallo, Sally A. see Min, David I., 610
 Fan, Chengde Accuracy of unbound-quinidine concentration determination after ultrafiltration, 917
 Fernández de Gatta, María del Mar Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies, 515
 Fox, A. W. Use and safety of sumatriptan (letter), 258
 Fraser, Gilles L. Vancomycin pharmacokinetics in elderly patients (letter), 481
 Frisolone, Julie Criteria for use of intravenous ciprofloxacin for infections in adult patients, 226
 Fruns, Ignacio see Fernández de Gatta, María del Mar, 515
 Frye, Carla B. see Underwood, Theodore W., 440
 Furmaga, Elaine M. Isolated systolic hypertension in older patients, 347

G

Gales, Barry J. see Gales, Mark A., 881
 Gales, Mark A. Recognition of severe cefixime-induced diarrhea (letter), 881
 Garnett, William R. Book review, 387
 Geraets, Douglas R. Atrial fibrillation and atrial flutter, 721
 Gill, Mark A. see Okamoto, Mark P., 134
 Giralt, Sergio see Ippoliti, Cindy, 520
 Glowacki, Robert C. see Rospond, Raylene M., 179
 Goemann, Marti Ketoconazole and gastric acidity (letter), 802
 Goldspiel, Barry R. Human gene therapy, 488
 Good, Chester B. Criteria for long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) in adult inpatients and outpatients, 780
 Goodin, Susan see Tsuaki, Tsuneo, 685
 Gray, Thomas M. Gentamicin pharmacokinetics in term

newborn twins, 615
 Greaney, James J. Jr. Ticlopidine-induced cholestatic jaundice (letter), 398
 Green, Laurence see Goldspiel, Barry R., 488
 Gregor, R. Elizabeth Paclitaxel: a new antineoplastic agent for refractory ovarian cancer, 401

H

Hale, Victoria G. Pharmacokinetics of oxaprozin (letter), 255
 Hall, Maura see Wallace, Carla S., 657
 Hall, Thomas G. Update on the medical treatment of hypercalcemia of malignancy, 117
 Hekmat, Elham see Oparaoji, Edward C., 131
 Helms, Richard A. see Christensen, Michael L., 606
 Heming, Deborah see Deamer, Robert L., 380
 Hernández, Jesús M. see Fernández de Gatta, María del Mar, 515
 Hess, David A. see Greaney, James J. Jr., 398
 Hiatt, Janet Criteria for use of warfarin in adult inpatients and outpatients, 307
 Hoehns, James D. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia, 814
 Hoffman, Elyse J. Flumazenil: a benzodiazepine antagonist, 641
 Holzinger, D. see Bunjes, R., 178
 Hruska, Barbara M. see Good, Chester B., 780
 Hsu, Van Doren Criteria for use of ticlopidine in adult inpatients and outpatients, 64
 Hsu, Van Doren Use and safety of sumatriptan (letter), 258

I

Ippoliti, Cindy Adverse effects of molgramostim in marrow transplant recipients, 520
 Ito, Matthew K. Computer dosing program for the initiation of vancomycin therapy, 126

J

Jaffe, Craig A. see Khanderia, Ujjaini, 774
 James, Robert E. III see Deamer, Robert L., 380
 James, Vivien E. see Artymowicz, Richard J., 563
 Janny, Laurent see Chopineau, Jean, 770
 Joch, Lois E. Accuracy of a first-order model for estimating initial heparin dosage, 597
 Johnson, Curtis A. see Ateshkadi, Arash, 34
 Johnson, Curtis A. see also Boheneck, Wayne S., 602
 Johnson, Jerry B. see DeVito, Joseph M., 293
 Johnston, Philip E. Book review, 704
 Jungnickel, Paul W. Relative safety and efficacy of pravastatin (letter), 257

K

Karnack, Charles M. Book review, 933
 Kavalsky, Robert A. see Lomaestro, Ben M., 693
 Kawaguchi, Yoshihiro see Ueno, Kazuyuki, 768
 Kerland, Heather Self-study materials review, 244
 Kessler, David A. MEDWatch: the new FDA medical products reporting program, 529
 Kessler, John M. Book review 934
 Khanderia, Ujjaini Amiodarone-induced thyroid dysfunction, 774
 Kienzle, Michael G. see Geraets, Douglas R., 721
 Kimelblatt, Bruce J. see Klausner, Mark A., 718
 Klausner, Mark A. Dosage of transdermal fentanyl (letter), 718
 Knupp, Catherine A. see Okamoto, Mark P., 134
 Koenker, Nancy see Deamer, Robert L., 380
 Koepel, Robin M. see Zenk, Karin E., 846
 Kozloski, Gary D. see DeVito, Joseph M., 293
 Krenzelok, Edward P. Judicious use of flumazenil (editorial), 691
 Kudsk, Kenneth A. see Binkley, Jeffrey F., 377
 Kuhn, Robert J. see Wallace, Carla S., 657

L

Labreche, Dustan G. Book review, 706
 Lam, Nancy P. see Ateshkadi, Arash, 34
 Lam, Y. W. Francis Fluorescence polarization immuno-

Annual Index

assay of quinidine, procainamide, and *N*-acetylprocainamide using Cobas-FFP reagents, 49

Lanao, José Martinez see Fernández de Gatta, María del Mar, 515

Leader, W. Greg see Rhoney, Denise H., 913

Leader, W. Greg see also Tsubaki, Tsuneo, 685

Leader, W. Greg see also Welch, Laura P., 909

Lesar, Timothy S. see Lomaestro, Ben M., 693

Lestico, Mitchell R. Polymyalgia rheumatica, 571

Leviton, Ira M. see Frisolone, Julie, 226

Lewis, Kelly S. see Michael, Katherine A., 150

Liem, Lorraine A. see Zenk, Karin E., 846

Lomaestro, Ben M. Pleurodesis with solution prepared from quinacrine hydrochloride tablets, 693

Lugo, Ralph A. Pathogenesis and treatment of bronchitis, 95

Lutomski, Dave M. see Joch, Lois E., 597

M

Mahoney, Charles D. see Greaney, James J., Jr., 398

Maiese, Susan see Ippoliti, Cindy, 520

Maillard, James A. see Respond, Raylene M., 179

Maloley, Pierre A. see Jungnickel, Paul W., 257

Manzo, John see Frisolone, Julie, 226

Marken, Patricia A. Criteria for use of lithium in adult inpatients and outpatients, 617

McCorvey, Eddie Jr. Book review, 867

McCorvey, Eddie Jr. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients, 300

McKenney, James M. see McCorvey, Eddie Jr., 300

Meister, Fred L. see Zeisler, John A., Jr., 527

Michael, Katherine A. Criteria for use of patient-controlled analgesia in adults, 150

Miller, Jane L. Conference, reports address public health implications of tuberculosis (News), 167

Miller, Jane L. Reviews of new drugs (editorial), 306

Miller, Lucinda G. Pharmacokinetics of oxaprozin (letter), 256

Min, David I. Encephalopathy associated with muramobab-CD3, 610

Mirtillo, Jay M. see Sunyecz, Lisa, 138

Moline, Margaret L. Pharmacologic strategies for managing premenstrual syndrome, 181

Montello, Michael J. see Baltz, Julie K., 805

Mowat-Lar森, Christine A. Specialized nutritional support in respiratory disease, 276

Murphy, Christine M. see Furmaga, Elaine M., 347

Murray, Michael D. Book review, 866

N

Nahata, Milap C. see Lugo, Ralph A., 95

Nakahiro, Randall K. see Okamoto, Mark P., 134

Naumann, Terryn L. see Shalansky, Stephen J., 483

Ninno, Mark A. Criteria for use of cyclosporine in adult transplant recipients, 696

O

Okamoto, Mark P. Cefepime pharmacokinetics in patients with acute cholecystitis undergoing cholecystectomy, 134

Oparaoji, Edward C. Aminoglycoside volume of distribution in postoperative patients with septic shock, 131

Orlando, Patricia L. Book review, 82

OXton, Lisa L. see Boheneck, Wayne S., 602

P

Page, Richard L. see Allen, Nancy M., 58

Palmieri, James see Alamillo, Cesar, 429

Perry, Paul J. see Hoehns, James D., 814

Phelps, Stephanie J. Infusion technology for predicting and detecting infiltration of peripheral intravenous catheter sites in infants, 216

Pickworth, Kerry K. Long-term dobutamine therapy (letter), 13

Poe, Timothy E. see Fox, A. W., 258

Povlow, Matthew J. Long-term dobutamine therapy (letter), 13

Powers, Douglas A. see Binkley, Jeffrey F., 377

Pritchard, John G. see Deamer, Robert L., 380

Proctor, Jack D. see McCrory, Eddie Jr., 300

Preziorka, Donna see Ippoliti, Cindy, 520

R

Raeber, Marsha A. Self-study material review, 548

Rawlings, D. Jim see Renfro, William H., 232

Reid, Dana J. Methotrexate for the treatment of chronic corticosteroid-dependent asthma, 762

Renfro, William H. Criteria for use of indomethacin injection in neonates, 232

Rhoney, Denise H. Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations, 913

Rogers, Susan J. Book review, 707

Rogers, Susan J. Pathophysiology and treatment of acute ischemic stroke, 359

Rospond, Raylene M. Dimethyl sulfoxide for treating anthracycline extravasation (Therapy Consultation), 560

Rospond, Raylene M. Sargramostim for sulfasalazine-induced agranulocytosis (letter), 179

Rumore, Martha M. Vitamin A as an immunomodulating agent, 506

S

San Miguel, Jesús F. see Fernández de Gatta, María del Mar, 515

Sargent, Andrea I. Seizure associated with ondansetron, 613

Sauvole, Valerie see Chopineau, Jean, 770

Schafer, C. see Bunjes, R., 178

Schaff, Robyn A. Burns see Hall, Thomas G., 117

Schoeffler, Pierre see Chopineau, Jean, 770

Schumacher, Gerald E. Book review, 323

Schuna, Arthur A. see Lestico, Mitchell R., 571

Schwinghammer, Terry L. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation, 736

Segars, Larry W. see Reid, Dana J., 762

Shaheen, Barbara E. Magnesium in the treatment of acute myocardial infarction, 588

Shalansky, Stephen J. Effect of flumazenil on benzodiazepine-induced respiratory depression, 483

Shepherd, Michele F. Bezoar formed by fragments of extended-release nifedipine tablets, 849

Shepherd, Michele F. Criteria for use of flumazenil in adult inpatients and outpatients, 536

Sherman, David G. see Rogers, Susan J., 359

Simonian, Jill S. see Ito, Matthew K., 126

Sirami, Suryanarayana see Oparaoji, Edward C., 131

Skovseth, Jon R. see Zeisler, John A., Jr., 527

Slimowitz, Richard Book review, 240, 864

Smith, Steven P. Book review, 241

Smith, Terry see Ippoliti, Cindy, 520

Spinler, Sarah A. see Cziraky, Mark J., 892

Spivey, J. Michael Criteria for use of ofloxacin and isofloxacin in adult inpatients and outpatients, 452

Sprott, Thomas T. see Yedinak, Kimberly C., 197

Steiner, Joseph F. Finasteride: a 5α-reductase inhibitor, 15

Storm, Michael C. see Christensen, Michael L., 606

Sunyecz, Lisa Sodium imbalance in a patient receiving total parenteral nutrition, 138

Symes, Laura R. see Walton, Ted, 261

T

Taketomo, Carol K. Book review, 787

Talley, C. Richard The new AIHP (editorial), 526

Tanaka, Kazuhiko see Ueno, Kazuyuki, 768

Terrisse, Marie-Pierre see Chopineau, Jean, 770

Theisen, Virginia see Khanderia, Ujjaini, 774

Tisdale, James E. see Fan, Chengde, 917

Tobert, Jonathan A. Relative safety and efficacy of pravastatin (letter), 256

Tolley, Elizabeth A. see Phelps, Stephanie J., 216

Tonelli, Alfred P. see DeVito, Joseph M., 293

Tsubaki, Tsuneo Estimation of creatinine clearance in patients with gynecological cancer, 685

U

Ueno, Kazuyuki Pharmacokinetics of mexiletine in middle-aged and elderly patients, 768

Ujhelyi, Michael R. see Fan, Chengde, 917

Umstead, Greg S. Self-study materials review, 243

Underwood, Theodore W. Drug-induced pancreatitis, 440

V

Valdés, Verónica see Anderson, Philip O., 479

Valley, Amy W. see Barron, Richard L., 853

Vaughn, Leigh M. Allergic bronchopulmonary aspergillosis, 24

Veal, Donna F. see Christensen, Michael L., 606

W

Wagner, Bertil K. J. Pharmacologic and clinical considerations in selecting crystalloid, colloidal, and oxygen-carrying resuscitation fluids, part 1, 335; part 2, 415

Wallace, Carla S. Pharmacologic management of cystic fibrosis, 657

Walton, Ted Felodipine and isradipine: New calcium-channel-blocking agents for the treatment of hypertension, 261

Warren, Eric W. see Hoffman, Elyse J., 641

Watkins, Cindy E. see Lam, Y. W. Francis, 49

Welch, Laura P. Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics, 909

Wheeler, Terrie see Good, Chester B., 780

Williams, Debra J. see Joch, Lois E., 597

Wingert, June see Bennett, Teresa A., 925

Witmer, David R. Comment on ASHP therapeutic guidelines (letter), 399

Wittkowsky, Ann K. see Hiatt, Janet, 307

Wojtylsak, Stacey L. see Binkley, Jeffrey F., 377

Wood, Warren A. Comment on ASHP therapeutic guidelines (letter), 399

Wright, Jackson T. Jr. see McCorvey, Eddie Jr., 300

Y

Yedinak, Kimberly C. Heparin and warfarin therapy after acute myocardial infarction, 197

Yellin, Albert E. see Okamoto, Mark P., 134

Z

Zanetti, Leslie A. Farquhar Sotalol: a new class III antiarrhythmic agent, 883

Zeisler, John A. Jr. Lidocaine therapy: time for re-evaluation, 527

Zellmer, William A. Context of a transition (editorial), 923

Zenk, Karin E. Comparative efficacy of glycerin enemas and suppository chips in neonates, 846

Zimmerman, Stephen W. see Boheneck, Wayne S., 602

Advertising Index

A

American Lung Association
Institutional, 558

American Society of Hospital Pharmacists
AHFS Drug Information 93, 94, 448, 525, 690
American Journal of Hospital Pharmacy, 828, 921
ASHP Membership, 177
ASHP Section of Home Care Practitioners, 882
Basic Skills in Interpreting Laboratory Data, 541, 609, 674
CiteSearch, 316
Clinical Pharmacokinetics Pocket Reference, 382, 400, 625, 635, 788, 862, 935
Clinical Pharmacy, 8, 149
Clinical Skills Program, Module 1: Reviewing Patient Medical Charts, 180, 275, 475, 587, 640, 779, 868, 891
Clinical Skills Program, Module 2: Building a Pharmacist's Data Base, 545, 559, 705, 784
Clinical Skills Program, Module 3: Constructing a Patient's Drug Therapy Problem List, 801, 880
Concepts in Immunology and Immunotherapy, 33
Concepts in Oncology Therapeutics, 14, 695
Criteria for Drug Use Evaluation: Volumes 1, 2, and 3, 73, 242, 616
Drug Information on CD, 540, 948
The Elements of Quality in Pharmaceutical Care, 125
George P. Provost Editorial Internship, 240
Guidelines for Administration of Intravenous Medications to Pediatric Patients, 137, 260, 543, 684, 803, 908
Handbook of Institutional Pharmacy Practice, 75
Handbook on Injectable Drugs and Supplement, 621
Handbook on Injectable Drugs, 7th Edition, 83
Home Infusion Software, 922
IPA Thesaurus, 399
IV-EASE, 317
Manual for Pharmacy Technicians, 459, 628
Medication Teaching Manual, 5th Edition, 547, 852
Medication Teaching Manual/MedTeach, 562, 714, 936
MedTeach, 259, 636
Pocket Guide to Injectable Drugs, 1993 Edition, 292, 514, 558, 788
Practical Aspects of Intravenous Drug Administration, 243, 428
QARx 3.0, 315
Supplement to the Handbook on Injectable Drugs, 708
Understanding Medical Terms: A Guide for Pharmacy Practice, 70

Amgen Inc.
Epogen, 4-5, 162-163, 168-169, 248-249, 332-333, 396-397, 472-473, 556-557, 638-639, 716-717, 798-799, 874-875
Neupogen, 77-80, 87-90, 319-322

ASHP Research and Education Foundation
Anticoagulation Clinic Traineeship Program, 482
Fellowships, 865

Asthma & Allergy Foundation of America
Institutional, 334

B

Burroughs Wellcome Company
Exosurf Neonatal, 9-12

C

CARE
Institutional, 82

Cook County Hospital
Positions Available, 715

Creighton University
Positions Available, 475

E

Egleston Children's Hospital
Position Available, 628

Eisenhower Medical Center
Position Available, 258

G

Good Samaritan Regional Medical Center
Position Available, 480

Greater Baltimore Medical Center
Position Available, 175

H

Harwood Academic Publishers
Journal of Applied Therapeutics, 334

The Hebrew University of Jerusalem
Position Available, 317

L

Lederle Laboratories, A Division of American Cyanamid Company
Institutional, 631, 711, 804

M

Micromedex, Inc.
Positions Available, 84, 239, 879

N

National Council on Patient Information and Education
Institutional, 706, 794

National Easter Seal Society
Institutional, 254

O

Ohio State University
Position Available, 164

P

PCS Health Systems, Inc.
Positions Available, 317, 334, 467

Pharmacon International, Inc.
Position Available, 384

Q

The Queen's Medical Center
Position Available, 467

R

Roche Laboratories, A Division of Hoffmann-La Roche Inc.
Rocephin, Feb IBC, OBC, Apr IBC, OBC, Jun IBC, OBC, Aug IBC, OBC, Oct IBC, OBC, Dec IBC, OBC
Romazicon, 791-792, 877-878

S

St. Jude Children's Research Hospital
Institutional, 480

SmithKline Beecham
Timentin, Jan IBC, OBC, Mar IBC, OBC, May IBC, OBC, Jul IBC, OBC, Sep IBC, OBC, Nov IBC, OBC

T

Third International Symposium on Oncology Pharmacy Practice
Symposium, 81

W

Wyeth-Ayerst Laboratories
Ativan Injection, 158-160, 172-174, 250-252, 328-330, 392-394, 476-478, 552-554, 633-634, 719-720, 795-796, 871-872
Tubex, Jan IFC, Feb IFC, Mar IFC, Apr IFC, May IFC, Jun IFC, Jul IFC, Aug IFC, Sep IFC, Oct IFC, Nov IFC, Dec IFC